,title,abstract,authors,link,ID,publication_date,update_date,subject,is_medRxiv
0,Suppression of COVID-19 infection by isolation time control based on the SIR model and an analogy from nuclear fusion research,"The coronavirus disease 2019 (COVID-19) has been damaging our daily life after declaration of pandemic. Therefore, we have started studying on the characteristics of Susceptible-Infectious-Recovered (SIR) model to know about the truth of infectious disease and our future. After detailed studies on the characteristics of the SIR model for the various parameter dependencies with respect to such as the outing restriction (lockdown) ratio and vaccination rate, we have finally noticed that the second term (isolation term) in the differential equation of the number of the infected is quite similar to the ""helium ash particle loss term"" in deuterium-tritium (D-T) nuclear fusion. Based on this analogy, we have found that isolation of the infected is not actively controlled in the SIR model. Then we introduce the isolation control time parameter q and have studied its effect on this pandemic. Required isolation time to terminate the COVID-19 can be estimated by this proposed method. To show this isolation control effect, we choose Tokyo for the model calculation because of high population density. We determine the reproduction number and the isolation ratio in the initial uncontrolled phase, and then the future number of the infected is estimated under various conditions. If the confirmed case can be isolated in 3~8 days by widely performed testing, this pandemic could be suppressed without awaiting vaccination. If the mild outing restriction and vaccination are taken together, the isolation control time can be longer. We consider this isolation time control might be the only solution to overcome the pandemic when vaccine is not available.","Mitarai, O.; Yanagi, N.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197723v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197723v1?rss=1,2020-09-20,2020-09-20,,True
1,Rapid transition to distance learning due to COVID-19: Perceptions of postgraduate dental learners and instructors,"Abstract The outbreak of COVID-19 necessitated abrupt transition from on campus, face-to-face sessions to online, distance learning in higher education institutions. The purpose of this study was to investigate the perceptions of postgraduate dental learners and instructors about the transition to distance learning, including the changes to the learning and teaching and its efficaciousness. A mixed-methods approach to research was utilized. All the instructors and postgraduate learners were invited to participate in the online survey. Quantitative data was analyzed using descriptive and inferential analyses on SPSS for Windows version 25.0, and for the responses to the open-ended questions, multi-staged Thematic Analysis was utilized. Both groups of stakeholders: learners and instructors, were quite satisfied with the rapid transition to distance learning due to COVID-19. Instructors were significantly more satisfied than the learners. The stakeholders adapted well to the change. The perception of the stakeholders regarding the case-based scenarios significantly influenced their level of satisfaction. As perceived by the stakeholders, the transition to distance learning entailed advantages and challenges. Going through the experience equipped the stakeholders with lessons learned and enabled them to develop informed opinions of how best to sustain learning and teaching irrespective of how matters unfold in relation to the pandemic. In conclusion, the worldwide dental education community faced unprecedented challenges due to the onset of COVID-19. Yet, in the grand scheme of things, it is important for decision-makers not to miss-out on the worthwhile opportunities, inherent in the experience, to reinforce curriculums, and maximize the learning and teaching.","Amir Rad, F.; Otaki, F.; baqain, Z.; Zary, N.; Al-Halabi, M.","https://www.medrxiv.org/content/10.1101/2020.09.19.20197830v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.19.20197830v1?rss=1,2020-09-20,2020-09-20,,True
2,Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays,"Background: Seroconversion panels (SCP) are an important tool for investigating antibody responses and developing serological assays. A SCP was generated from a single SARS-CoV-2 positive plasma donor over 87 days. Methods: This SCP was tested against five SARS-CoV-2 antibody tests (IgG, IgM and total Ig). All test kits utilized recombinant antigens that are specific to SARS-CoV-2. Results: The SCP showed IgG responses for SARS-CoV-2 after day 50. IgM levels peaked on day 50 (prior to IgG) and declined in subsequent samples. Conclusion: This SCP is a useful tool for validation of SARS-CoV-2 antibody assays.","Belda, F.; Cherenzia, R.; Crowley, M.","https://www.medrxiv.org/content/10.1101/2020.09.08.20190256v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.08.20190256v1?rss=1,2020-09-20,2020-09-20,,True
3,SARS-CoV-2 antigen and antibody prevalence among UK staff working with cancer patients during the COVID-19 pandemic.,"Background International guidelines for testing potentially immunosuppressed cancer patients receiving non-surgical anticancer therapies for SARS-CoV-2 (COVID-19) are currently lacking. The value of routinely testing staff treating cancer patients is not known. Methods: Patient-facing oncology department staff at work during the COVID-19 pandemic consented to have a nasopharyngeal swab SARS-CoV-2 antigen test by polymerase chain reaction (PCR) and blood tests for SARS-CoV-2 antibody using a laboratory Luminex-based assay and a rapid point-of-care (POC) assay on 2 occasions 28 days apart in June and July 2020. Results 434 participants were recruited: nurses (58.3%), doctors (21.2%), radiographers (10.4%) and administrators (10.1%). 82% were female; median age 40-years (range 19-66). 26.3% reported prior symptoms suggestive of SARS-CoV-2 infection and 1.4% tested PCR-positive prior to June 2020. All were PCR-negative at both study day 1 and 28. 18.4% were SARS-CoV-2 sero-positive on day 1 by Luminex, of whom 42.5% also tested positive by POC. 47.5% of Luminex sero-positives had antibodies to both nucleocapsid (N) and surface (S) antigens. Nurses (21.3%) and doctors (17.4%) had higher prevalence trends of Luminex sero-positivity compared with administrators (13.6%) and radiographers (8.9%) (p=0.2). 38% of sero-positive participants reported previous symptoms suggestive of SARS-CoV-2 infection, a 1.9-fold higher odds than sero-negative participants (p=0.01). 400 participants re-tested on day 28: 13.3% were Luminex sero-positive of whom 92.5% were previously positive and 7.5% newly positive. Nurses (16.5%) had the highest seroprevalence trend amongst staff groups (p=0.07). 32.5% of day 1 sero-positives became sero-negative by day 28: the majority being previously reactive to the N-antigen only (p<0.0001). Conclusion The high prevalence of SARS-CoV-2 IgG sero-positivity in oncology nurses, and the high decline of positivity over 4 weeks supports regular antigen and antibody testing in this staff group for SARS-CoV-2 as part of routine patient care prior to availability of a vaccine.","Favara, D. M.; McAdam, K.; Cooke, A.; Bordessa-Kelly, A.; Budriunaite, I.; Bossingham, S.; Houghton, S.; Doffinger, R.; Ainsworth, N.; Corrie, P.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197590v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197590v1?rss=1,2020-09-20,2020-09-20,,True
4,SARS-CoV-2 PCR cycle threshold at hospital admission associated with Patient Mortality,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The relationship of initial Ct at hospitalization and patient mortality has not been thoroughly investigated. Methods and findings We conducted a retrospective study of all SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS CoV-2 Ct data within 48 hours of admission (n=1044). Only patients with complete survival data discharged (n=774) or died in hospital (n=270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct values were analyzed both as continuous variables and subdivided into quartiles to better illustrate their relationship with outcomes, and other covariates. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. In this cohort the mean Ct at admission was higher for survivors (28.6, SD=5.8) compared to non-survivors (24.8, SD=6.0, P<0.001). Patients with a lower Ct value on admission were found to have a higher odds ratio (0.91, CI 0.89-0.94, p<0.001) of in hospital mortality after adjusting for age, gender, body mass index (BMI) and history of hypertension and diabetes. Patients with Ct values in 3rd Quartile (Ct 27.4-32.8) and 4th Quartile (Ct >32.9) have a lower odds of in-hospital death (P<0.001) in comparison to the 1st Quartile. On comparing between Ct quartiles, the mortality, BMI and glomerular filtration rate (GFR) were significantly different (p<0.05) between the groups. The cumulative incidence of all-cause mortality and discharge was found to differ between Ct quartiles (Grays Test P<0.001 for both.) Conclusion: SARS-CoV-2 Ct at admission was found to be an independent predictor of in patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test.","Choudhuri, J.; Carter, J.; Nelson, R.; Skalina, K.; Osterbur-Badhey, M.; Johnson, A.; Goldstein, D. Y.; Paroder, M.; Szymanski, J.","https://www.medrxiv.org/content/10.1101/2020.09.16.20195941v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195941v1?rss=1,2020-09-20,2020-09-20,,True
5,The Effects of Indias COVID-19 Lockdown on Critical Non-COVID Health Care and Outcomes,"Indias COVID-19 lockdown is widely believed to have disrupted critical health services, but its effect on non-COVID health outcomes is largely unknown. Comparing mortality trends among dialysis patients in the eight months around the lockdown with the previous year, we document a 64% increase in mortality between March and May 2020 and an estimated 22-25% total excess mortality through July 2020. The mortality increase is greater among females and disadvantaged groups. Barriers to transportation and disruptions in hospital services appear to be the main drivers of increased morbidity and mortality. The results highlight the unintended consequences of the lockdown on critical and life-saving non-COVID health services that must be taken into account in the implementation of future policy efforts to control the spread of pandemics.","Jain, R.; Dupas, P.","https://www.medrxiv.org/content/10.1101/2020.09.19.20196915v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.19.20196915v1?rss=1,2020-09-20,2020-09-20,,True
6,An immunodominance hierarchy exists in CD8+ T cell responses to HLA-A*02:01-restricted epitopes identified from the non-structural polyprotein 1a of SARS-CoV-2.,"COVID-19 vaccines are being rapidly developed and human trials are underway. Almost all of these vaccines have been designed to induce antibodies targeting spike protein of SARS-CoV-2 in expectation of neutralizing activities. However, non-neutralizing antibodies are at risk of causing antibody-dependent enhancement. Further, the longevity of SARS-CoV-2-specific antibodies is very short. Therefore, in addition to antibody-induced vaccines, novel vaccines on the basis of SARS-CoV-2-specific cytotoxic T lymphocytes (CTLs) should be considered in the vaccine development. Here, we attempted to identify HLA-A*02:01-restricted CTL epitopes derived from the non-structural polyprotein 1a of SARS-CoV-2. Eighty-two peptides were firstly predicted as epitope candidates on bioinformatics. Fifty-four in 82 peptides showed high or medium binding affinities to HLA-A*02:01. HLA-A*02:01 transgenic mice were then immunized with each of the 54 peptides encapsulated into liposomes. The intracellular cytokine staining assay revealed that 18 out of 54 peptides were CTL epitopes because of the induction of IFN-g-producing CD8+ T cells. In the 18 peptides, 10 peptides were chosen for the following analyses because of their high responses. To identify dominant CTL epitopes, mice were immunized with liposomes containing the mixture of the 10 peptides. Some peptides were shown to be statistically predominant over the other peptides. Surprisingly, all mice immunized with the liposomal 10 peptide mixture did not show the same reaction pattern to the 10 peptides. There were three pattern types that varied sequentially, suggesting the existence of an immunodominance hierarchy, which may provide us more variations in the epitope selection for designing CTL-based COVID-19 vaccines.","Takagi, A.; Matsui, M.","https://www.biorxiv.org/content/10.1101/2020.09.18.304493v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.18.304493v1?rss=1,2020-09-19,2020-09-19,,False
7,Antisense oligonucleotides target a nearly invariant structural element from the SARS-CoV-2 genome and drive RNA degradation,"The SARS-CoV-2 virus contains an unusually large, single-stranded RNA genome that is punctuated with structured elements of unknown function, such as the s2m element located in the 3' untranslated region. The evolutionary conservation of the s2m element and its occurrence in all viral subgenomic transcripts implicates a key role in the viral infection cycle. In order to exploit this element as a potential therapeutic target, we have designed antisense gapmer oligonucleotides that efficiently base-pair to the s2m region. These oligonucleotides, composed of locked nucleic acids (LNA) flanking a central DNA core, successfully remodel the s2m structure and induce sequence-specific RNA cleavage by RNase H in vitro. Gapmers are also effective in human cells as they reduce the fluorescence signal in GFP reporter assays and cause a dose-dependent reduction in replication in a model replicon system based on a human astrovirus. Overall, these oligonucleotides show promise as anti-viral agents and may serve as a helpful starting point to develop treatments for COVID-19.","Lulla, V.; Wandel, M. P.; Bandyra, K. J.; Dendooven, T.; Yang, X.; Doyle, N.; Oerum, S.; O'Rourke, S.; Randow, F.; Maier, H. J.; Scott, W.; Ding, Y.; Firth, A.; Bloznelyte, K.; Luisi, B.","https://www.biorxiv.org/content/10.1101/2020.09.18.304139v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.18.304139v1?rss=1,2020-09-19,2020-09-19,,False
8,Environmental and climatic impact on the infection and mortality of SARS-CoV-2 in Peru,"The role of the environment and climate in the transmission and case-fatality rates of SARS-CoV-2 is still being investigated. Elevation and air quality are believed to be significant factors in the current development of the pandemic, but the influence of additional environmental factors remain unclear. In this study, we explored the relationship between the cumulative number of infections and mortality cases with climate (temperature, precipitation, solar radiation, water vapor pressure, wind), environmental data (elevation, NDVI, PM2.5 and NO2 concentration), and population density in Peru. Using the data from confirmed cases of infection from 1287 districts and confirmed cases of mortality in 479 districts, we used Spearman's correlations to assess the correlation between environmental and climatic factors with cumulative infection cases, cumulative mortality and case-fatality rate. We also explored district cases by the ecozones of coast, sierra, high montane forest and lowland rainforest. Multiple linear regression models indicate elevation, mean solar radiation, air quality, population density and green cover are influential factors in the distribution of infection and mortality of SARS-CoV-2 in Peru. The case-fatality rate was weakly associated with elevation. Our results also strongly suggest that exposure to poor air quality is a significant factor in the mortality of individuals with SARS-CoV-2 below the age of 30. We conclude that environmental and climatic factors do play a significant role in the transmission and case-fatality rates in Peru, however further study is required to see if these relationships are maintained over time.","Samillan, V. J.; Flores-Leon, D.; Zutta, B. R.; Rojas, E.","https://www.medrxiv.org/content/10.1101/2020.09.16.20196170v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20196170v1?rss=1,2020-09-18,2020-09-18,,True
9,"Epidemiology of SARS-CoV-2 infection in Karnataka State, South India: Transmission dynamics of symptomatic vs. asymptomatic infections","Background: In this report, we describe the epidemiology of SARS-CoV-2 infection, specifically examining how the symptomatic persons drove the transmission in the state of Karnataka, India, during the lockdown phase. Methods: The study included all the cases reported from March 8 to May 31, 2020 in the state. Any person with history of international or domestic travel from high burden states, those presenting with Influenza-like or Severe Acute Respiratory Illness and high-risk contacts of COVID19 cases, who were SARS-CoV-2 RT-PCR positive were included. Detailed analysis based on contact tracing data available from line-list of the state surveillance unit was performed using cluster analysis software package. Findings: Amongst the 3404 COVID-19 positive cases, 3096 (91%) were asymptomatic while 308 (9%) were symptomatic. Majority of the asymptomatic cases were in the age range of 16-50 years while symptomatic cases were between 31-65 years. Most of those affected were males. Cluster analysis of 822 cases indicated that the secondary attack rate, size of the cluster (dispersion) and occurrence of overt clinical illness is significantly higher when the index case in a cluster was symptomatic compared to an asymptomatic. Interpretation: Our findings indicate that both asymptomatic and symptomatic SARS-CoV-2 cases transmit the infection; however, the main driving force behind the spread of infection within the state was significantly higher from symptomatic cases. This has major implications for policies related to testing. Active search for symptomatic cases, subjecting them to testing and treatment should be prioritized for containing the spread of COVID-19.","Kumar, N.; Hameed, S. K. S.; Babu, G. R.; Venkataswamy, M. M.; Dinesh, P.; Kumar, P. B. G.; John, D. A.; Desai, A.; Vasanthapuram, R.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196501v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196501v1?rss=1,2020-09-18,2020-09-18,,True
10,Factors associated with the spatial heterogeneity of COVID-19 in France: a nationwide ecological study,"Like in many countries and regions, spread of the COVID 19 pandemic has exhibited important spatial heterogeneity across France, one of the most affected countries so far. To better understand factors associated with incidence, mortality and lethality heterogeneity across the 96 administrative departments of metropolitan France, we thus conducted a geoepidemiological analysis based on publicly available data, using hierarchical ascendant classification (HAC) on principal component analysis (PCA) of multidimensional variables, and multivariate analyses with generalized additive models (GAM). Our results confirm a marked spatial heterogeneity of in-hospital COVID 19 incidence and mortality, following the North East / South West diffusion of the epidemic. The delay elapsed between the first COVID-19 associated death and the onset of the national lockdown on March 17th, 2020, appeared positively associated with in-hospital incidence, mortality and lethality. Mortality was also strongly associated with incidence. Mortality and lethality rates were significantly higher in departments with older population, but they were not significantly associated with the number of intensive-care beds available in 2018. We did not find any significant association between incidence, mortality or lethality rates and incidence of new chloroquine and hydroxychloroquine dispensations in pharmacies either, nor between COVID 19 incidence and climate, nor between economic indicators and in-hospital COVID 19 incidence or mortality. This ecological study highlights the impact of population age structure, epidemic spread and transmission mitigation policies in COVID-19 morbidity or mortality heterogeneity.","Gaudart, J.; Landier, J.; huiart, l.; Legendre, E.; Lehot, L.; Bendiane, M.-K.; Chiche, L.; Petitjean, A.; Mosnier, E.; Kirakoya-samadoulougou, F.; Demongeot, J.; Piarroux, R.; Rebaudet, S.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196360v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196360v1?rss=1,2020-09-18,2020-09-18,,True
11,"The COVID-19 Spread in the State of Assam, India","We have studied the current COVID-19 spread situation in Assam, a State of India. We have found that currently the spread pattern is indeed exponential and that it is not going to show a reducing trend soon. As a result, it is not possible yet to forecast about the time of peaking of the epidemic in Assam. It can be said that the COVID-19 situation in this Indian State is very alarming even after five and a half months of the start of the epidemic in the State. It may so happen that in Assam the spread would continue to grow exponentially even after the situation changes in India as a whole.","Baruah, H. K.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197095v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197095v1?rss=1,2020-09-18,2020-09-18,,True
12,Identification of potential biomarkers and inhibitors for SARS-CoV-2 infection,"The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed many health systems globally. Here, we aim to identify biological markers and associated biological processes of COVID-19 using a bioinformatics approach to elucidate their potential pathogenesis. The gene expression profile of the GSE152418 dataset was originally produced by using the high-throughput Illumina NovaSeq 6000. Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) and Gene Ontology (GO) enrichment analyses were applied to identify functional categories and biochemical pathways. KEGG and GO results suggested that biological pathways such as Cancer pathways and Insulin pathways were mostly affected in the development of COVID-19. Moreover, we identified several genes including EP300, CREBBP, and POLR2A were involved in the virus activities in COVID-19 patients. We further predicted that some inhibitors may have the potential to block the SARS-CoV-2 infection based on the L1000FWD analysis. Therefore, our study provides further insights into the underlying pathogenesis of COVID-19.","Gu, H.; Yuan, G.","https://www.medrxiv.org/content/10.1101/2020.09.15.20195487v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.15.20195487v1?rss=1,2020-09-18,2020-09-18,,True
13,Cost-effective serological test to determine exposure to SARS-CoV-2: ELISA based on the receptor-binding domain of the spike protein (Spike-RBDN318-V510) expressed in Escherichia coli,"Massive worldwide serological testing for SARS-CoV-2 is needed to determine the extent of virus exposure in a particular region, the ratio of symptomatic to asymptomatic infected persons, and the duration and extent of immunity after infection. To achieve this aim, the development and production of reliable and cost-effective SARS-CoV-2 antigens is critical. Here, we report the bacterial production of the peptide S-RBDN318-V510, which contains the receptor binding domain of the SARS-CoV-2 spike protein. We purified this peptide using a straightforward approach involving bacterial lysis, his-tag mediated affinity chromatography, and imidazole-assisted refolding. The antigen performances of S RBDN318 V510 and a commercial full-length spike protein were compared in two distinct ELISAs. In direct ELISAs, where the antigen was directly bound to the ELISA surface, both antigens discriminated sera from non-exposed and exposed individuals. However, the discriminating resolution was better in ELISAs that used the full-spike antigen than the S-RBDN318-V510. Attachment of the antigens to the ELISA surface using a layer of anti-histidine antibodies gave equivalent resolution for both S-RBDN318-V510 and the full length spike protein. Our results demonstrate that ELISA-functional SARS-CoV-2 antigens can be produced in bacterial cultures. S-RBDN318-V510 is amenable to massive production and may represent a cost-effective alternative to the use of structurally more complex antigens in serological COVID-19 testing.","Marquez-Ipina, A. R.; Gonzalez-Gonzalez, E.; Rodriguez-Sanchez, I. P.; Lara-Mayorga, I. M.; Mejia-Manzano, L. A.; Gonzalez-Valdez, J. G.; Ortiz-Lopez, R.; Rojas-Martinez, A.; Trujillo-de Santiago, G.; Alvarez, M. M.","https://www.medrxiv.org/content/10.1101/2020.09.15.20195503v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.15.20195503v1?rss=1,2020-09-18,2020-09-18,,True
14,Urban rail transport and SARS-CoV-2 infections: an ecological study in Lisbon Metropolitan Area,"Introduction: Large number of passengers, limited space and shared surfaces can transform public transportation into a hub of epidemic spread. This study was conducted to investigate whether proximity to railway stations, a proxy for utilization, was associated with higher rates of SARS-CoV-2 infection across small-areas of Lisbon Metropolitan Area (Portugal). Methods: The number of SARS-CoV-2 confirmed infections from March 2 until July 5, 2020 at parish-level was obtained from the National Epidemiological Surveillance System. We used a Geographic Information System to estimate proximity to railway stations from the six railway lines operating in the area. Then, we fitted a quasi-Poisson generalized linear regression model to estimate the relative risks (RR) and corresponding 95% Confidence Intervals (95%CI). Results: Between May 2 and July 5, 2020, there were a total of 17,168 SARS-CoV-2 infections in the Lisbon Metropolitan Area, with wide disparities between parishes. Globally, parishes near one of the railway lines (Sintra) presented significantly higher SARS-CoV-2 infection rates (RR=1.42, 95%CI 1.16, 1.75) compared to those parishes located far away from railway stations, while the opposite happened for parishes near other railway lines (Sado/Fertagus), whose infection rates were significantly lower than those observed in parishes located far away from railway stations (RR=0.66, 95%CI 0.50, 0.87). However, the associations varied according to the stage of the epidemic and according to mitigation measures in place. Regression results also revealed an increasing influence of socioeconomic deprivation on SARS-CoV-2 infections. Conclusions: We found no consistent association between proximity to railway stations and SARS-CoV-2 infection rates in the most affected metropolitan area of the country, suggesting that other factors (e.g. socioeconomic deprivation) might play a more prominent role in the epidemic dynamics.","Severo, M.; Ribeiro, A. I.; Lucas, R.; Leao, T.; Barros, H.","https://www.medrxiv.org/content/10.1101/2020.09.18.20195776v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20195776v1?rss=1,2020-09-18,2020-09-18,,True
15,Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials,"Background: Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aimed to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. Methods: Rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/). We systematically identified published and unpublished RCTs by September 14, 2020 (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, PubMed, Cochrane COVID-19 registry). All-cause mortality was extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine/chloroquine. Prespecified subgroup analyses included patient setting, diagnostic confirmation, control type, and publication status. Results: Sixty-two trials were potentially eligible. We included 16 unpublished trials (1596 patients) and 10 publications/preprints (6317 patients). The combined summary OR on all-cause mortality for hydroxychloroquine was 1.08 (95%CI: 0.99, 1.18; I-square=0%; 24 trials; 7659 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I-square=0%; 4 trials; 307 patients). We identified no subgroup effects. Conclusions: We found no benefit of hydroxychloroquine or chloroquine on the survival of COVID-19 patients. For hydroxychloroquine, the confidence interval is compatible with increased mortality (OR 1.18) or negligibly reduced mortality (OR 0.99). Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.","Axfors, C.; Schmitt, A. M.; Janiaud, P.; van 't Hooft, J.; Abd-Elsalam, S.; Abdo, E. F.; Abella, B. S.; Akram, J.; Amaravadi, R. K.; Angus, D. C.; Arabi, Y. M.; Azhar, S.; Baden, L. R.; Baker, A. W.; Belkhir, L.; Benfield, T.; Berrevoets, M. A. H.; Chen, C.-P.; Chen, T.-C.; Cheng, S.-H.; Cheng, C.-Y.; Chung, W.-S.; Cohen, Y. Z.; Cowan, L. N.; Dalgard, O.; de Almeida e Val, F. F.; de Lacerda, M. V. G.; de Melo, G. C.; Derde, L.; Dubee, V.; Elfakir, A.; Gordon, A. C.; Hernandez-Cardenas, C. M.; Hills, T.; Hoepelman, A. I. M.; Huang, Y.-W.; Igau, B.; Jin, R.; Jurado-Camacho, F.; Khan, K. S.; Kremsner, P. G.; Kreuels, B.; Kuo, C.-Y.; Le, T.; Lin, Y.-C.; Lin, W.-P.; Lin, T.-H.; Nakrem Lyngbakken, M.; McArthur, C.; McVerry, B.; Meza-Meneses, P.; Monteiro, W. M.; Morpeth, S. C.; Mourad, A.; Mulligan, M. J.; Murthy, S.; Naggie, S.; Narayanasamy, S.; Nichol, A.; Novack, L. A.; O'Brien, S. M.; Okeke, N. L.; Perez, L.; Perez-Padilla, R.; Perrin, L.; Remigio-Luna, A.; Rivera-Martinez, N. E.; Rockhold, F. W.; Rodriguez-Llamazares, S.; Rolfe, R.; Rosa, R.; Rosjo, H.; Sampaio, V. S.; Seto, T. B.; Shehzad, M.; Soliman, S.; Stout, J. E.; Thirion-Romero, I.; Troxel, A. B.; Tseng, T.-Y.; Turner, N. A.; Ulrich, R. J.; Walsh, S. R.; Webb, S. A.; Weehuizen, J. M.; Velinova, M.; Wong, H.-L.; Wrenn, R.; Zampieri, F. G.; Zhong, W.; Moher, D.; Goodman, S. N.; Ioannidis, J. P. A.; Hemkens, L. G.","https://www.medrxiv.org/content/10.1101/2020.09.16.20194571v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20194571v1?rss=1,2020-09-18,2020-09-18,,True
16,The impact of vital signs on the death of patients with new coronavirus pneumonia: A systematic review and meta-analysis,"Background: Assessing the impact of vital signs (blood pressure, body temperature, heart rate, respiratory rate, and oxygen saturation) on the death of patients with new coronavirus pneumonia would provide a simple and convenient method for the monitoring of subsequent illness, and therefore, in some degree reduce treatment costs and increase the cure rate clinically. Methods: Six databases were retrieved. The software R 3.6.2 was used for meta-analysis of the included literature. Results: 12 studies were included, which comprise 8996 patients affected with COVID-19 infection. The meta-analysis study found that blood pressure (MAP, SBP and DBP), heart rate, respiration rate and SpO2 are the risk factors for disease progression in patients with COVID-19. Among them, the increase in MAP and the decrease in SpO2 have the greatest impact on the death of patients with COVID-19 [MAP: MD = 5.66, 95% CI (0.34, 10.98), SpO2: MD = -5.87, 95% CI (-9.17, -2.57), P = 0.0005]. However, comparing the body temperature of the death group and the survival group found that the body temperature was not statistically significant between the two groups [body temperature: MD = 0.21, 95% CI (-0.01, 0.43), P = 0.0661]. Conclusion: The increase in MAP, heart rate and respiratory rate, as well as the decrease in SBP, DBP and SpO2 are all independent risk factors for death in patients with COVID-19. These factors are simple and easy to monitor, and individualized treatment can be given to patients in time, reducing the mortality rate and improving treatment efficiency.","Du, M.; Zhao, J.; Yin, X.; Zhang, N.; Zheng, G.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196709v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196709v1?rss=1,2020-09-18,2020-09-18,,True
17,"Multifractal behavior of SARS-CoV-2 COVID-19 pandemic spread, case of: Algeria, Russia, USA and Italy.","Here, the multifractal behavior of the SARS-CoV-2 COVID-19 pandemic daily and death cases is investigated through the so-called Wavelet Transform Modulus Maxima lines (WTMM) method, data available via the World Health Organization (WHO) dashboard of Algeria, Russia, USA and Italy are analyzed. Obtained results show the multifractal behavior of the COVID-19 pandemic data with different spectra of singularities. Keywords: Multifractal behavior, daily and death cases, WTMM, COVID-19 pandemic data","Ouadfeul, S.-A.","https://www.medrxiv.org/content/10.1101/2020.09.16.20196188v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20196188v1?rss=1,2020-09-18,2020-09-18,,True
18,Model-based and model-free characterization of epidemic outbreaks,"Here we provide detailed background information for our work on Bayesian inference of change-points in the spread of SARS-CoV-2 and the effectiveness of non-pharmaceutical interventions (Dehning et al., Science, 2020). We outline the general background of Bayesian inference and of SIR-like models. We explain the assumptions that underlie model-based estimates of the reproduction number and compare them to the assumptions that underlie model-free estimates, such as used in the Robert-Koch Institute situation reports. We highlight effects that originate from the two estimation approaches, and how they may cause differences in the inferred reproduction number. Furthermore, we explore the challenges that originate from data availability - such as publication delays and inconsistent testing - and explain their impact on the time-course of inferred case numbers. Along with alternative data sources, this allowed us to cross-check and verify our previous results.","Dehning, J.; Spitzner, F. P.; Linden, M. C.; Mohr, S. B.; Pinheiro Neto, J.; Zierenberg, J.; Wibral, M.; Wilczek, M.; Priesemann, V.","https://www.medrxiv.org/content/10.1101/2020.09.16.20187484v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20187484v1?rss=1,2020-09-18,2020-09-18,,True
19,"Relations between demographic, geographic, and environmental statistics, and the spread of novel coronavirus disease (COVID-19) in Italy","Background: From January 2020, the COVID-19 pandemic has raged around the world, causing nearly a million deaths and hundreds of severe economic crises. In this terrible scenario, Italy was one of the most affected countries. ------------ Objective: The aim of this study is to look for significant correlations between COVID-19 cases and demographic, geographical, and environmental statistics of each Italian region from February 26 to August 12, 2020. Finally, we further investigated the link between SARS-CoV-2 spread and particulate matter 2.5 and 10 concentrations before the lockdown in Lombardy. ------------ Methods: All demographic data were taken from the AdminStat Italia website, while the geographic data from the Il Meteo website. The collection frequency was 1 week. Data on PM2.5 and PM10 average daily concentrations were collected from previously published articles. We used Pearson's coefficients to correlate quantities that followed a normal distribution, and Spearman's coefficient to correlate quantities that did not follow a normal distribution. To evaluate this, we used the kurtosis (k) and skewness (s) coefficients according to the following scheme: we considered data compatible with a normal distribution only when t_k=k(24/n)^(-1/2) [&le;] 1.5 and t_s=s(6/n)^(-1/2) [&le;] 1.5; here, the Pearson correlation index was deemed more reliable. When t_k in ]1.5,3],t_s [&le;] 3 or t_k [&le;] 3, t_s in ]1.5,3], we considered it appropriate to evaluate both correlations. Finally, when t_k,t_s > 3, we judged the Spearman correlation index more appropriate. When the linear correlations were significant, we interpolated the data linearly. We reported in round brackets () the week in which the correlation approached the threshold of statistical significance e.g. Abruzzo (4). The chosen p-value threshold was =.05. ------------ Results: We found significant strong correlations between COVID-19 cases and population density in 60.0% of regions, such as Calabria (5), Campania (1), Lazio (1), Liguria (2), Lombardy (4), Piedmont (2), Sardinia (3), Sicily (1), and Veneto (4) (R_best=.935, 95% CI: .830 -1.000,p_best=.046,95% CI:.006-.040). The average of the angular coefficients resulting from the linear interpolations of the pairs (COVID-19 cases, population number) is b=.0037 (95% CI .0009-.0065). We found a significant strong correlation between the angular coefficients b of the various regions and their latitude. This data shows the dependence of COVID-19 on geographical and/or climatic factors (R=.926,p=.001,r=.886,p=.003). in particular, we found a significant correlation with the historical averages (last 30 years) of the minimum temperatures of the Italian regions (R=-.849,p=.008,r=-.940,p=.005 for March, R=-.923,p=.001,r=-.872,p = .005 for February). We found a significant strong correlation between the number of COVID-19 cases until August 12 and the average daily concentrations of PM2.5 in Lombardy until February 29, 2020 (r=.76,p=.004). No significant correlation with PM10 was found in the same periods. Until February 26, 2020, we found both a correlation with PM2.5 (r=.63,p=.029) and PM10 (r=.72,p=.009). In the second week of March, the correlation with PM10 disappeared while that with PM2.5 continued to exist until nowadays. We found that 40 g/m^3 for PM2.5 and 50 g/m^3 for PM10 are plausible thresholds beyond which particulate pollution clearly favors the spread of SARS-CoV-2. ------------ Conclusion: Since SARS-CoV-2 is correlated with historical minimum temperatures and particulate matter 10 and 2.5, health authorities are urged to monitor pollution levels and to invest in precautions for the arrival of autumn. Furthermore, we suggest creating awareness campaigns for the recirculation of air in closed places and to avoid exposure to cold.","Rovetta, A.; Castaldo, L.","https://www.medrxiv.org/content/10.1101/2020.09.18.20196980v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20196980v1?rss=1,2020-09-18,2020-09-18,,True
20,A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro,"Effective intervention strategies are urgently needed to control the COVID-19 pandemic. Human angiotensin-converting enzyme 2 (ACE2) is a carboxypeptidase that forms a dimer and serves as the cellular receptor for SARS-CoV-2. It is also a key negative regulator of the renin-angiotensin system (RAS), conserved in mammals, which modulates vascular functions. We report here the properties of a trimeric ACE2 variant, created by a structure-based approach, with binding affinity of ~60 pM for the spike (S) protein of SARS-CoV-2, while preserving the wildtype peptidase activity as well as the ability to block activation of angiotensin II receptor type 1 in the RAS. Moreover, the engineered ACE2 potently inhibits infection of SARS-CoV-2 in cell culture. These results suggest that engineered, trimeric ACE2 may be a promising anti-SARS-CoV-2 agent for treating COVID-19.","Xiao, T.; Lu, J.; Zhang, J.; Johnson, R. I.; McKay, L. G. A.; Storm, N.; Lavine, C. L.; Peng, H.; Cai, Y.; Rits-Volloch, S.; Lu, S.; Quinlan, B. D.; Farzan, M.; Seaman, M. S.; Griffiths, A.; Chen, B.","https://www.biorxiv.org/content/10.1101/2020.09.18.301952v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.18.301952v1?rss=1,2020-09-18,2020-09-18,,False
21,Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells,"The SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with currently 29 million confirmed cases and close to a million deaths. At this time, there are no FDA-approved vaccines or therapeutics for COVID-19, but Emergency Use Authorization has been granted for remdesivir, a broad-spectrum antiviral nucleoside analog. However, remdesivir is only moderately efficacious against SARS-CoV-2 in the clinic, and improved treatment strategies are urgently needed. To accomplish this goal, we devised a strategy to identify compounds that act synergistically with remdesivir in preventing SARS-CoV-2 replication. We conducted combinatorial high-throughput screening in the presence of submaximal remdesivir concentrations, using a human lung epithelial cell line infected with a clinical isolate of SARS-CoV-2. We identified 20 approved drugs that act synergistically with remdesivir, many with favorable pharmacokinetic and safety profiles. Strongest effects were observed with established antivirals, Hepatitis C virus nonstructural protein 5 A (HCV NS5A) inhibitors velpatasvir and elbasvir. Combination with their partner drugs sofosbuvir and grazoprevir further increased efficacy, increasing remdesivir's apparent potency 25-fold. We therefore suggest that the FDA-approved Hepatitis C therapeutics Epclusa (velpatasvir/sofosbuvir) and Zepatier (elbasvir/grazoprevir) should be fast-tracked for clinical evaluation in combination with remdesivir to improve treatment of acute SARS-CoV-2 infections.","Nguyenla, X.; Wehri, E.; Van Dis, E.; Biering, S.; Yamashiro, L. H.; Stroumza, J.; Dugast-Darzacq, C.; Graham, T.; Stanley, S.; Schaletzky, J.","https://www.biorxiv.org/content/10.1101/2020.09.18.302398v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.18.302398v1?rss=1,2020-09-18,2020-09-18,,False
22,The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity,"Despite a rapidly growing body of literature on COVID-19, our understanding of the immune correlates of disease severity, course and outcome remains poor. Using mass cytometry, we assessed the immune landscape in longitudinal whole blood specimens from 59 patients presenting with acute COVID-19, and classified based on maximal disease severity. Hospitalized patients negative for SARS-CoV-2 were used as controls. We found that the immune landscape in COVID-19 forms three dominant clusters, which correlate with disease severity. Longitudinal analysis identified a pattern of productive innate and adaptive immune responses in individuals who have a moderate disease course, whereas those with severe disease have features suggestive of a protracted and dysregulated immune response. Further, we identified coordinate immune alterations accompanying clinical improvement and decline that were also seen in patients who received IL-6 pathway blockade. The hospitalized COVID-19 negative cohort allowed us to identify immune alterations that were shared between severe COVID-19 and other critically ill patients. Collectively, our findings indicate that selection of immune interventions should be based in part on disease presentation and early disease trajectory due to the profound differences in the immune response in those with mild to moderate disease and those with the most severe disease.","Bolouri, H.; Speake, C.; Skibinski, D.; Long, S. A.; Hocking, A. M.; Campbell, D. J.; Hamerman, J. A.; Malhotra, U.; Buckner, J. H.; BRI COVID-19 Research Team,","https://www.biorxiv.org/content/10.1101/2020.09.18.303420v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.18.303420v1?rss=1,2020-09-18,2020-09-18,,False
23,Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model,"The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the prime target for vaccine development. The spike protein mediates both binding to host cells and membrane fusion and is also so far the only known viral target of neutralizing antibodies. Coronavirus spike proteins are large trimers that are relatively instable, a feature that might be enhanced by the presence of a polybasic cleavage site in the SARS-CoV-2 spike. Exchange of K986 and V987 to prolines has been shown to stabilize the trimers of SARS-CoV-1 and the Middle Eastern respiratory syndrome coronavirus spikes. Here, we test multiple versions of a soluble spike protein for their immunogenicity and protective effect against SARS-CoV-2 challenge in a mouse model that transiently expresses human angiotensin converting enzyme 2 via adenovirus transduction. Variants tested include spike protein with a deleted polybasic cleavage site, the proline mutations, a combination thereof, as well as the wild type protein. While all versions of the protein were able to induce neutralizing antibodies, only the antigen with both a deleted cleavage site and the PP mutations completely protected from challenge in this mouse model.

ImportanceA vaccine for SARS-CoV-2 is urgently needed. A better understanding of antigen design and attributes that vaccine candidates need to have to induce protective immunity is of high importance. The data presented here validates the choice of antigens that contain the PP mutation and suggests that deletion of the polybasic cleavage site could lead to a further optimized design.","Amanat, F.; Strohmeier, S.; Rathnasinghe, R.; Schotsaert, M.; Coughlan, L.; Garcia-Sastre, A.; Krammer, F.","https://www.biorxiv.org/content/10.1101/2020.09.16.300970v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300970v1?rss=1,2020-09-18,2020-09-18,,False
24,Physiological Effect of Prone Positioning in Mechanically Ventilated SARS- CoV-2 Infected Patients with Severe ARDS: Preliminary Analysis of an Observational Study,"Prone position ventilation has been shown to decrease mortality and improve oxygenation in ARDS patients. With best of our knowledge, no study reported physiological effect of prone position in SARS- CoV-2 infected ARDS patients. In this prospective observational study, data of n=20 consecutive laboratory confirmed SARS- CoV-2 patients with severe ARDS as per Berlin definition was included. Data of 20 patients analyzed with a median (Interquartile range, IQR) age of 56 (45.5- 67) y and median (IQR) P/F ratio of 56 (54- 66) with a median (IQR) PEEP of 12 (12- 14) before initiation of prone position. Seventy-five percentage (95% CI 53.1- 88.8) patients were prone responders at 16h prone session and 50 (95% CI 29.9- 70.1) % patients were sustained responders. There was a significant decrease in plateau airway pressure (p<0.0001), peak airway pressure (p<0.0001) and driving pressure(p<0.0001) and increase in static compliance (p=0.001), P/F ratio (p<0.0001), PaO2 (p=0.0002)and SpO2 (p=0.0004) at 4h and 16h since initiation of prone session and also after return of supine position. Prone position in SARS- CoV-2 infected severe ARDS patients is associated with improvement in lung compliance and oxygenation in two- third of the patients and persisted in half of the patients.","Roy, A.; Behera, S.; Pande, A.; Bhattacharjee, A.; Bhattacharyya, A.; Baidya, D. K.; Anand, R. K.; Ray, B. R.; Subramaniam, R.; Maitra, S.","https://www.medrxiv.org/content/10.1101/2020.09.16.20195958v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195958v1?rss=1,2020-09-18,2020-09-18,,True
25,Seroprevalence of Antibodies to SARS-CoV-2 in US Blood Donors,"Background To identify blood donors eligible to donate Coronavirus Disease-2019 (COVID-19) Convalescent Plasma (CCP), a large blood center began testing for antibodies to SARS-CoV-2, the etiologic agent of COVID-19. We report the seroprevalence of total immunoglobulin directed against the S1 spike protein of SARS-CoV-2 in US blood donors. Methods Unique non-CCP donor sera from June 1-July 31, 2020 were tested with the Ortho VITROS Anti-SARS-CoV-2 total immunoglobulin assay (positive: signal-to-cutoff (S/C) =>1). Donor age, sex, race/ethnicity, ABO/RhD, education, and experience were compared to June and July 2019. Multivariate regressions were conducted to identify demographics associated with the presence of antibodies and with S/C values. Results Unique donors (n=252,882) showed an overall seroprevalence of 1.83% in June (1.37%) and July (2.26%), with the highest prevalence in northern New Jersey (7.3%). In a subset of donors with demographic information (n=189,565), higher odds of antibody reactivity were associated with non-Hispanic Native American/Alaskan (NH-NAA/A) and Black (NH-B), and Hispanic (H) race/ethnicity, age 18-64, middle school or lesser education, blood Group A, and never or non-recent donor status. In positive donors (n=2,831), antibody signal was associated with male sex, race/ethnicity (NH-NAA/A, NH-B and H) and geographic location. Conclusions Seroprevalence remains low in US blood donors but varies significantly by region. Temporal trends in reactivity may be used to gauge the effectiveness of public health measures. Before generalizing these data from healthy donors to the general population however, rates must be corrected for false positive test results among low prevalence test subjects and adjusted to match the wider demography.","Vassallo, R. R.; Bravo, M. D.; Dumont, L. J.; Hazegh, K.; Kamel, H.","https://www.medrxiv.org/content/10.1101/2020.09.17.20195131v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20195131v1?rss=1,2020-09-18,2020-09-18,,True
26,In the long shadow of our best intentions: model-based assessment of the consequences of school reopening during the COVID-19 pandemic,"As the United States grapples with the ongoing COVID-19 pandemic, a particularly thorny set of questions surrounds the reopening of K-12 schools and universities. The benefits of in-person learning are numerous, in terms of education quality, mental health, emotional well-being, equity and access to food and shelter. Early reports suggested that children might have reduced susceptibility to COVID-19, and children have been shown to experience fewer complications than older adults. Over the past few months, our understanding of COVID-19 has been further shaped by emerging data, and it is now understood that children are as susceptible to infection as adults and have a similar viral load during infection. While the higher prevalence of asymptomatic disease among children makes symptom-based isolation strategies ineffective, asymptomatic patients do not in fact carry a reduced viral load. Based on this updated understanding of the disease, we have used epidemiological modeling to explore the feasibility and consequences of school reopening in the face of differing rates of COVID-19 prevalence and transmission. Our findings indicate that, regardless of the initial prevalence of the disease, and in the absence of systematic surveillance testing, most schools in the United States can expect to remain open for 20-60 days. At this point, one or more large disease clusters can be expected to be detected, forcing schools to close again. These disease clusters, in turn, can be expected to propagate through the community, with potentially hundreds to thousands of additional cases resulting from each individual school cluster. Thus, our findings suggest that the debate between the risks to student safety and benefits of in-person learning frames a false dual choice. Given the current circumstances in the United States, the most likely outcome in the late fall is that students will be deprived of the benefits of in-person learning while having incurred a significant risk to themselves and their communities.","Johnson, K. E.; Stoddard, M.; Nolan, R. P.; White, D. E.; Hochberg, N. S.; Chakravarty, A.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197400v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197400v1?rss=1,2020-09-18,2020-09-18,,True
27,Detectability of the novel coronavirus (SARS-CoV-2) infection and rates of mortality for COVID-19 in different regions of the Russian Federation,"Background: Laboratory diagnosis of the novel coronavirus (SARS-CoV-2) infection combined with quarantine for contacts of infected individuals affects the spread of SARS-CoV-2 in the community and the levels of related mortality. Moreover, not all cases of SARS-CoV-2 infection in the population are detected (laboratory diagnosed). Here, we examine the relation between detectability of SARS-CoV-2 infection (i.e. the percent of detected COVID-19 cases among all cases of SARS-CoV-2 infection in the population) and levels of mortality for COVID-19 for the 85 different regions (federal subjects) of the Russian Federation. Methods: Lower case-fatality ratio (i.e. the ratio between the number of reported COVID-19 deaths and the number of diagnosed cases of SARS-CoV-2 infection in the population) corresponds to higher detectability of the SARS-COV-2 infection. We used data from the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) on the number of detected COVID-19 cases and the number of deaths from COVID-19 in the 85 different regions of the Russian Federation to examine the correlation between case-fatality ratios and rates of mortality for COVID-19 in different regions of the Russian Federation. Results: The correlation between case-fatality ratios for cases/deaths reported by Sep. 17, 2020 and rates of mortality for COVID-19 per 100,000 for deaths reported by Sep. 17, 2020 in different regions of the Russian Federation is 0.68 (0.55,0.78), with the region with both the highest COVID-19 mortality rate per 100,000 and the highest case-fatality ratio being the city of St. Petersburg. Conclusions: Detectability of SARS-CoV-2 infection is one of the factors that affects the levels of mortality for COVID-19 in Russia. Regions of the Russian Federation with relatively low detectability of SARS-CoV-2 infection (e.g. those regions for which the case-fatality ratio is above the median value of 0.012 for the case-fatality ratio in different regions of the Russian Federation on Sep. 17, 2020 [3]) ought to increase testing for SARS-CoV-2 in order to mitigate the spread of SARS-CoV-2 and diminish the related mortality.","Goldstein, E.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197194v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197194v1?rss=1,2020-09-18,2020-09-18,,True
28,Apparent reductions in COVID-19 Case Fatality Rates reflect changes in average age of those testing positive.,"Numbers of COVID-19 infections are rising in many countries, while death and hospitalisation rates remain low. Infection Fatality Rates (IFR) for individual year classes calculated from seroprevalence data and the ages of those dying in England show a very strong log-linear relationship with age, and allow us to predict fatality rates for those testing positive on each day based on their ages. Since the peak of the epidemic, reductions in the ages of cases account for an eight fold fall in fatality rates. Over the same period, increased testing intensity appears to have increased infections detected amongst the most vulnerable by a factor of at least five, and between 15 and 24 fold in the population as a whole. Together these two factors are sufficient to explain the large observed change in the ratio of deaths to reported cases. We can also use these methods to give a more precise early warning system of future increases in mortality rates than raw case numbers. Although case numbers are currently increasing markedly, a continuing reduction in numbers of older individuals being infected means that the predicted increase in mortality rates is much slower.","Grant, A.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197160v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197160v1?rss=1,2020-09-18,2020-09-18,,True
29,Genomic epidemiology of the Los Angeles COVID-19 outbreak,"Los Angeles (LA) County has sustained a large outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To learn about the transmission history of SARS-CoV-2 in LA County, we sequenced 142 viral genomes from unique patients seeking care at UCLA Health System. 86 of these genomes are from samples collected before April 19, 2020. We found that the early outbreak in LA, as in other international air travel hubs, was seeded by multiple introductions of strains from Asia and Europe. We identified a US-specific strain, B.1.43, which has been found predominantly in California and Washington State. While samples from LA County carry the ancestral B.1.43 genome, viral genomes from neighbouring counties in California and from counties in Washington State carry additional mutations, suggesting a potential origin of B.1.43 in Southern California. We quantified the transmission rate of SARS-CoV-2 over time, and found evidence that the public health measures put in place in LA County to control the virus were effective at preventing transmission, but may have been undermined by the many introductions of SARS-CoV-2 into the region. Our work demonstrates that genome sequencing can be a powerful tool for investigating outbreaks and informing the public health response. Our results reinforce the critical need for the U.S. to have coordinated inter-state responses to the pandemic.","Guo, L.; Boocock, J.; Hilt, E.; Chandrasekaran, S.; Zhang, Y.; Munugala, C.; Sathe, L.; Alexander, N.; Arboleda, V. A.; Flint, J.; Eskin, E.; Luo, C.; Yang, S.; Garner, O. B.; Yin, Y.; Bloom, J. S.; Kruglyak, L.","https://www.medrxiv.org/content/10.1101/2020.09.15.20194712v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.15.20194712v1?rss=1,2020-09-18,2020-09-18,,True
30,"Seroprevalence and seroconversion rates to SARS-CoV-2 in interns, residents, and medical doctors in a University Hospital in Bogota, Colombia","Objectives To determine the prevalence of antibodies to SARS-CoV-2 and the incidence of seroconversion in the first month of follow-up among interns, residents, and medical doctors attending patients at a University Hospital, to explore for associations of seroprevalence and seroconversion with risk factors and symptoms compatible with COVID-19, and to explore the concordance of CLA, LFA, and ELFA. Design or methods We conducted a cross-sectional and a prospective study among medical doctors and medical trainees at Hospital Universitario San Ignacio in Bogota (Colombia) during June, July, and August to assess seroprevalence and seroconversion rates in this population was performed using CLA IgG for SARS-CoV-2. LFA IgG and IgM and ELFA IgM were also determined to explore concordance with CLA IgG. Results At baseline, 8 (2.28% 95%CI 1.16-4.43%) individuals were IgG positive for SARS-CoV-2 by CLA. At the end of the study, 21 (5.98% 95%CI 3.94-8.97%) individuals seroconverted by CLA IgG. In all, 29 individuals had IgG by CLA and of these 11 (3.13% 95%CI 1.76-5.52%) were asymptomatic. No associations with risk factors for infection were identified. CLA had moderate concordance with LFA IgG and ELFA, but minimal with LFA IgM. Conclusions Our report is one of the first in Latina America on seroprevalence and seroconversion rates in medical healthcare workers. It emphasizes the importance of avoiding focusing only on symptomatic individuals to screen this population for SARS-CoV-2 infection, since of all individuals that have evidence of previous infection many (37.93%) may be pre-symptomatic or asymptomatic and may contribute to infection/disease spread.","Ariza, B. E.; Torres, Y. X.; Salgado, D.; Cepeda, M.; Gomez, C.; Castellanos, J. C.; Suarez, F.; Cuellar, A.; Cardozo, C. C.; Angel, J.; Franco, M. A.","https://www.medrxiv.org/content/10.1101/2020.09.15.20195313v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.15.20195313v1?rss=1,2020-09-18,2020-09-18,,True
31,CLINICALLY DISTINCT COVID-19 CASES SHARE STRIKINGLY SIMILAR IMMUNE RESPONSE PROGRESSION: A FOLLOW-UP ANALYSIS,"Inflammatory responses to the novel coronavirus SARS-CoV-2, which causes COVID-19, range from asymptomatic to severe. Here we present a follow-up analysis of a longitudinal study characterizing COVID-19 immune responses from a father and son with distinctly different clinical courses. The father required a lengthy hospital stay for severe symptoms, whereas his son had mild symptoms and no fever yet tested positive for SARS-CoV-2 for 29 days. Father and son, as well as another unrelated COVID-19 patient, displayed a robust increase of SERPING1, the transcript encoding C1 esterase inhibitor (C1-INH). We further bolstered this finding by incorporating a serum proteomics dataset and found that serum C1-INH was consistently increased in COVID-19 patients. C1-INH is a central regulator of the contact and complement systems, potentially linking COVID-19 to complement hyperactivation, fibrin clot formation, and immune depression. Furthermore, despite distinct clinical cases, significant parallels were observed in transcripts involved interferon and B cell signaling. As symptoms were resolving, widespread decreases were seen in immune-related transcripts to levels below those of healthy controls. Our study provides insight into the immune responses of likely millions of people with extremely mild symptoms who may not be aware of their infection with SARS-CoV-2 and implies a potential for long-lasting consequences that could contribute to reinfection risk.","Hausburg, M.; Banton, K. L.; Roshon, M.; Bar-Or, D.","https://www.medrxiv.org/content/10.1101/2020.09.16.20115972v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20115972v1?rss=1,2020-09-18,2020-09-18,,True
32,The epidemiological characteristics of COVID-19 in Libya during the ongoing-armed conflict.,"Abstract Introduction: COVID-19 can have even more dire consequences in countries with ongoing armed conflict. Libya, the second largest African country, has been involved in a major conflict since 2011. This study analyzed the epidemiological situation of the COVID-19 pandemic in Libya, examined the impact of the armed conflict in Libya on the spread of the pandemic, and proposes strategies for dealing with the pandemic during this conflict. Methods: We collected the available information on all COVID-19 cases in the different regions of Libya, covering the period from March 25 to May 25, 2020. The cumulative number of cases and the daily new cases are presented in a way to illustrate the patterns and trends of COVID-19 and the effect of the ongoing armed conflict was assessed regionally. Results: A total of 698 cases of COVID-19 were reported in Libya during a period of three months. The number of cases varied from one region to another and was affected by the fighting. The largest number of cases was reported in the southern part of the country, which has been severely affected by the conflict in comparison to the eastern and western parts of the country. Conclusion: This study describes the epidemiological pattern of COVID-19 in Libya and how it has been affected by the ongoing armed conflict. This conflict seems to have hindered access to populations and thereby masked the true dimensions of the pandemic. Hence, efforts should be combined to combat these consequences.","Daw, M. A.; El-Bouzedi, A. H.; Ahmed, M. O.; Alejenef, A. A.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196352v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196352v1?rss=1,2020-09-18,2020-09-18,,True
33,How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.gov,"Objective: The novel coronavirus disease (COVID-19), broke out in December 2019, is a global pandemic. Rapidly in the past few months, a large number of clinical studies have been initiated worldwide to find effective therapeutics, vaccines, and preventive strategies. In this study, we aim to understand the landscape of COVID-19 clinical research and identify the gaps and issues that may cause difficulty in recruitment and the lack of population representativeness. Materials and Methods: We analyzed 2,034 COVID-19 studies registered in the largest public registry - ClinicalTrials.gov. Leveraging natural language processing, descriptive analysis, association analysis, and clustering analysis, we characterized COVID-19 clinical studies by phase and design features. Particularly, we analyzed their eligibility criteria to understand: (1) whether they considered the reported underlying health conditions that may lead to severe illnesses, and (2) if these studies excluded older adults, either explicitly or implicitly, which may reduce the generalizability of these studies in older adults. Results: The 5 most frequently tested drugs are Hydroxychloroquine (N=148), Azithromycin (N=46), Tocilizumab (N=29), Lopinavir (N=20), and Ritonavir (N=20). Most trials did not have an upper age limit and did not exclude patients with common chronic conditions such as hypertension and diabetes that are prevalent in older adults. However, known risk factors that may lead to severe illnesses have not been adequately considered by existing studies. Conclusions: A careful examination of the registered COVID-19 clinical studies can identify the research gaps and inform future COVID-19 trial design towards balanced internal validity and generalizability.","He, Z.; Erdengasileng, F.; Luo, X.; Xing, A.; Charness, N.; Bian, J.","https://www.medrxiv.org/content/10.1101/2020.09.16.20195552v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195552v1?rss=1,2020-09-18,2020-09-18,,True
34,Inflammatory leptomeningeal cytokines mediate delayed COVID-19 encephalopathy,"SARS-CoV-2 infection induces a wide spectrum of neurologic dysfunction. Here we show that a particularly vulnerable population with neurologic manifestations of COVID-19 harbor an influx of inflammatory cytokines within the cerebrospinal fluid in the absence of viral neuro-invasion. The majority of these inflammatory mediators are driven by type 2 interferon and are known to induce neuronal injury in other disease models. Levels of matrix metalloproteinase-10 within the spinal fluid correlate with the degree of neurologic dysfunction. Furthermore, this neuroinflammatory process persists weeks following convalescence from the acute respiratory infection. These prolonged neurologic sequelae following a systemic cytokine release syndrome lead to long-term neurocognitive dysfunction with a wide range of phenotypes.","Remsik, J.; Wilcox, J. A.; Babady, N. E.; McMillen, T.; Vachha, B. A.; Halpern, N. A.; Dhawan, V.; Rosenblum, M.; Iacobuzio-Donahue, C. A.; Avila, E. K.; Santomasso, B.; Boire, A.","https://www.medrxiv.org/content/10.1101/2020.09.15.20195511v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.15.20195511v1?rss=1,2020-09-18,2020-09-18,,True
35,The Peak of COVID-19 in India,"Abstract Introduction: Following the USA, India ranks the second position in the world for COVID 19 cases with the highest number of daily confirmed cases since September 2020. The peak of COVID-19 cases is the most warranted feature for understanding the curvature of COVID 19 cases. Aim: This study aims to analyse the growth rates of the daily confirmed cases and to provide an expected count of the peak of daily confirmed cases. Data: We retrieved data from an Application Programming Interface portal https://www.covid19india.org/ which is open access and publicly available. Methods: Exponential model was applied to estimate the growth rates of daily confirmed cases. The estimated growth rates were used for calculating the doubling time. The Lotka Euler method was applied to calculate the effective reproduction rate. SARIMA model was developed for the growth rates to predict daily confirmed cases. Results: Results show the best fit of the exponential model over the daily confirmed cases. The growth rates estimated from the exponential model shows an unsteady, modest decline. Doubling time shows a linear increase. The effective reproduction rate declined from 3.6 persons in the third week of March 2020 to 1.14 persons at the end of August 2020. The diagnosis of the developed SARIMA model confirmed no trends in the residuals, no outliers, and nearly constant variance. The forecast suggests the peak value of daily confirmed cases would waver around 105,000 counts in the last week of September 2020. The cumulative COVID-19 cases would account for approximately 105 lakhs at the end of December 2020. Conclusion: The exponential model unravels a shift and a modest decline in the growth of daily confirmed cases. The trends in R(t) show analogue with the trends in growth rates of daily confirmed cases. The study shows that the SARIMA model is suitable for projecting daily confirmed cases. The results shed light on the understanding of the trends and epidemiological stage of COVID-19 disease, in the cognisance of the peak. Contribution: This study based on moments of the distribution of the daily confirmed cases of COVID-19 disease unravels the uncertainty about the peak and curvature of COVID-19 disease. Keywords: COVID-19, SARS-CoV-2, Exponential model, ARIMA, Effective Reproduction rate, Growth rates, Pandemic","Yadav, S.; YADAV, P. K.","https://www.medrxiv.org/content/10.1101/2020.09.17.20197087v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20197087v1?rss=1,2020-09-18,2020-09-18,,True
36,Metabolic stress and disease-stage specific basigin expression of peripheral blood immune cell subsets in COVID-19 patients,"Coronavirus disease 2019 (COVID-19) is driven by dysregulated immune responses yet the role of immunometabolism in COVID-19 pathogenesis remains unclear. By investigating 47 patients with confirmed SARS-CoV-2 infection and 16 uninfected controls, we found an immunometabolic dysregulation specific for patients with progressed disease that was reversible in the recovery phase. Specifically, T cells and monocytes exhibited increased mitochondrial mass, accumulated intracellular ROS and these changes were accompanied by disrupted mitochondrial architecture. Basigin (CD147), but not established markers of T cell activation, was up-regulated on T cells from progressed COVID-19 patients and correlated with ROS accumulation, reflected in the transcriptome. During recovery, basigin and ROS decreased to match the uninfected controls. In vitro analyses confirmed the correlation and showed a down-regulation of ROS by dexamethasone treatment. Our findings provide evidence of a basigin-related and reversible immunometabolic dysregulation in COVID-19.","Siska, P. J.; Singer, K.; Klitzke, J.; Kauer, N.; Decking, S.-M.; Bruss, C.; Matos, C.; Kolodova, K.; Peuker, A.; Schoenhammer, G.; Raithel, J.; Lunz, D.; Graf, B.; Geismann, F.; Lubnow, M.; Mack, M.; Hau, P.; Bohr, C.; Burkhardt, R.; Gessner, A.; Salzberger, B.; Hanses, F.; Hitzenbichler, F.; Heudobler, D.; Lueke, F.; Pukrop, T.; Herr, W.; Wolff, D.; Poeck, H.; Brochhausen, C.; Hoffmann, P.; Rehli, M.; Kreutz, M.; Renner, K.","https://www.medrxiv.org/content/10.1101/2020.09.18.20194175v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20194175v1?rss=1,2020-09-18,2020-09-18,,True
37,IMPACT OF UNIVERSITY RE-OPENING ON TOTAL COMMUNITY COVID-19 BURDEN,"Purpose: Post-secondary students have higher than average contacts than the general population due to congregate living, use of public transit, high-density academic and social activities, and employment in the services sector. We evaluated the impact of a large student population returning to a mid-sized city currently experiencing a low rate of COVID-19 on community health outcomes. We consider whether targeted routine or one-time screening in this population can mitigate community COVID-19 impacts. Methods: We developed a dynamic transmission model of COVID-19 subdivided into three interacting populations: general population, university students, and long-term care residents. We parameterized the model using the medical literature and expert opinion. We calibrated the model to the observed outcomes in a mid-sized Canadian city between March 1 and August 15, 2020 prior to the arrival of a relatively large post-secondary student population. We evaluated the impact of the student population (20,000 people arriving on September 1) on cumulative COVID-19 infections over the fall semester, the timing of peak infections, the timing and peak level of critical care occupancy, and the timing of re-engaged social and economic restrictions. We consider multiple scenarios with different student and general population COVID-19 prevention behaviours as well as different COVID-19 screening strategies in students. Results: In a city with low levels of COVID-19 activity, the return of a relatively large student population substantially increases the total number of COVID-19 infections in the community. In a scenario in which students immediately engage in a 24% contact reduction compared to pre-COVID levels, the total number of infections in the community increases by 87% (from 3,900 without the students to 7,299 infections with the students), with 71% of the incremental infections occurring in the general population, causing social and economic restrictions to be re-engaged 3 weeks earlier and an incremental 17 COVID-19 deaths. Scenarios in which students have an initial, short-term increase in contacts with other students before engaging in contact reduction behaviours can increase infections in the community by 150% or more. In such scenarios, screening asymptomatic students every 5 days reduces the number of infections attributable to the introduction of the university student population by 42% and delays the re-engagement of social and economic restrictions by 1 week. Compared to screening every 5 days, one-time mass screening of students prevents fewer infections, but is highly efficient in terms of infections prevented per screening test performed. Discussion: University students are highly inter-connected with the city communities in which they live and go to school, and they have a higher number of contacts than the general population. High density living environments, enthusiasm for the new school year, and relatively high rates of asymptomatic presentation may decrease their self-protective behaviours and contribute to increased community transmission of COVID-19 affecting at-risk members of the city community. Screening targeted at this population provides significant public health benefits to the community through averted infections, critical care admissions, and COVID-19 deaths.","Cipriano, L. E.; Haddara, W. M. R.; Zaric, G. S.; Enns, E. A.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197467v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197467v1?rss=1,2020-09-18,2020-09-18,,True
38,COVID-19 pediatric mortality rates are heterogenous between countries,"Introduction: Severe COVID-19 is infrequent in children, with a lethality rate of about 0.08%. This study aims to explore differences in the pediatric mortality rate between countries. Methods: Countries with populations over 5 million that report COVID-19 deaths disaggregated data by quinquennial or decennial age groups were analyzed. Data were extracted from COVID-19 Cases and Deaths by Age Database, national ministries of health, and the World Health Organization. Results: 23 countries were included in the analysis. Pediatric mortality varied from 0 to 12.1 deaths per million people of the corresponding age group, with the highest rate in Peru. In most countries, deaths were more frequent in the 0-4 years old age group, except for Brazil. The pediatric/ general COVID-19 mortality showed a great variation between countries and ranged from 0 (Republic of Korea) to 10.4% (India). Pediatric and Pediatric/general COVID mortality have a strong correlation with 2018 neonatal mortality (r=0.77, p<0.001 and r= 0.88, p<0.001 respectively), while it has a moderate or absent (r=0.47, p=0.02 and r=0.19, p=0.38, respectively) correlation with COVID-19 mortality in the general population. Conclusions: There is an important heterogenicity in pediatric COVI-19 mortality between countries that parallels historical neonatal mortality. Neonatal mortality is a known index of the quality of a country s Health System which points to the importance of social determinants of health in pediatric COVID-19 mortality disparities, an issue which should be further explored.","Gonzalez-Garcia, N.; Miranda-Lora, A. L.; Mendez-Galvan, J.; Granados-Riveron, J. T.; Nieto-Zermeno, J.; Garduno-Espiosa, J.; CASTILLA-PEON, M. F.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196832v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196832v1?rss=1,2020-09-18,2020-09-18,,True
39,Clinical-epidemiological and treatment characteristics of children with COVID-19 in a tertiary referral center in Peru,"Introduction The COVID-19 pandemic has a great impact on children's health. This study describes the clinical, epidemiological and treatment characteristics of children presenting COVID-19 at the Instituto Nacional de Salud del Nino San Borja (INSN-SB) Methods This was a retrospective study of patients with a confirmed diagnosis of COVID-19 from March to July 2020. Demographic, clinical, laboratory, radiological, and treatment information were collected. Data analysis included descriptive statistics and bivariate analysis to determine differences between patients in general wards and the intensive care unit (ICU). Results We included 91 patients, 33 being females (36.3%). The most affected age group was children > 2 years of age (63 cases) with a median age of 6 years (IQR 3-10), and 61.5% were from Lima. The previous contact was determined in 30.8% of cases. A positive SARS CoV-2 PCR result was obtained in 50.6%. The presence of comorbidity was 53.8%. The most frequent symptoms were: fever (39.6%), general malaise (23.1%), cough (19.8%), and respiratory distress (14.3%). The presence of multisystem inflammatory syndrome in children (MIS-C) was confirmed in 6 patients. Antibiotics were administered in 76.9%. The most frequent radiological pattern was bilateral interstitial infiltrates (57.7%). Mortality was higher in patients in the ICU than in the hospitalization ward (27.3% vs. 4.3%, respectively; p = 0.02) Conclusions COVID-19 in children presents mild and moderate clinical manifestations. The presence of comorbidity is an important factor for hospitalization, and mortality is high upon admission to critical care units.","Chiara-Chilet, C.; Luna-Vilchez, M.; Maquera-Afaray, J.; Salazar-Mesones, B.; Portillo-Alvarez, D.; Priale-Miranda, R.; Mendoza-Torres, F.; Munayco-Perez, A.; Baca-Cama, Y.; Santiago-Abad, M.; Lopez, J. W.; Pediatric COVID-19 Working Group INSN SB,","https://www.medrxiv.org/content/10.1101/2020.09.18.20186866v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20186866v1?rss=1,2020-09-18,2020-09-18,,True
40,"Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes","Importance: Understanding transmission and impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in school children is critical to implement appropriate mitigation measures. Objective: To determine the variation in SARS-CoV-2 seroprevalence in school children across districts, schools, grades, and classes, and the relationship of SARS-CoV-2 seroprevalence with self-reported symptoms. Design: Cross-sectional analysis of baseline measurements of a longitudinal cohort study (Ciao Corona) from June-July 2020. Setting: 55 randomly selected schools and classes stratified by district in the canton of Zurich, Switzerland (1.5 million inhabitants). Participants: Children, aged 6-16 years old, attending grades 1-2, 4-5 and 7-8. Exposure: Exposure to circulating SARS-CoV-2 between February and June 2020 including public lock-down and school closure (March 16-May 10, 2020). Main Outcomes and Measures: Variation in seroprevalence of SARS-CoV-2 in children across 12 cantonal districts, schools, and grades using a Luminex-based antibody test with four targets for each of IgG, IgA and IgM. Clustering of cases within classes. Analysis of associations of seropositivity and symptoms. Comparison of seroprevalence with a randomly selected adult population, based on Luminex-based IgG and IgA antibody test of Corona Immunitas. Results: In total, 55 schools and 2585 children were recruited (1337 girls, median age 11, age range 6-16 years). Overall seroprevalence was 2.8 % (95% CI 1.6-4.1%), ranging from 1.0% to 4.5% across districts. Seroprevalence was 3.8% (1.9-6.1%) in grades 1-2, 2.5% (1.1-4.2%) in grades 4-5, and 1.5% (0.5-3.0%) in grades 7-8. At least one case was present in 36/55 tested schools and in 43/128 classes with [&ge;]50% participation rate and [&ge;]5 children tested. 73% of children reported COVID-19 compatible symptoms since January 2020, but none were reported more frequently in seropositive compared to seronegative children. Seroprevalence of children was very similar to seroprevalence of randomly selected adults in the same region in June-July 2020, measured with the same Corona Immunitas test, combining IgG and IgA (3.1%, 95% CI 1.4-5.4%, versus 3.3%, 95% CI 1.4-5.5%). Conclusions and Relevance: Seroprevalence was inversely related to age and revealed a dark figure of around 90 when compared to 0.03% confirmed PCR+ cases in children in the same area by end of June. We did not find clustering of SARS-CoV-2 seropositive cases in schools so far, but the follow-up of this school-based study will shed more light on transmission within and outside schools. Trial registration: ClinicalTrials.gov Identifier: NCT04448717, registered June 26, 2020. https://clinicaltrials.gov/ct2/show/NCT04448717","Ulyte, A.; Radtke, T.; Abela, I. A.; Haile, S. H.; Blankenberger, J.; Jung, R.; Capelli, C.; Berger, C.; Frei, A.; Huber, M.; Schanz, M.; Schwarzmueller, M.; Trkola, A.; Fehr, J.; Puhan, M. A.; Kriemler, S.","https://www.medrxiv.org/content/10.1101/2020.09.18.20191254v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20191254v1?rss=1,2020-09-18,2020-09-18,,True
41,"SARS-CoV-2 antibody seroprevalence in Tbilisi, the capital city of country of Georgia","Background: Georgia timely implemented effective response measures, with testing, contact tracing and isolation being the main pillar of the national response, achieving the lowest cumulative incidence of SARS-CoV-2 in the European region. Methods: We conducted a survey to estimate SARS-CoV-2 IgG antibody seroprevalence among adult residents of capital city of Tbilisi (adult population: 859,328). Participants were recruited through respondent driven sampling during May 18-27, 2020. Blood specimens were tested for SARS-CoV-2 IgG antibodies using commercially available lateral flow immunoassay (COVID-19 IgG/IgM Rapid Test Cassette, Zhejiang Orient Gene Biotech). Crude seroprevalence was weighted by population characteristics (age, sex, district of Tbilisi) and further adjusted for test accuracy. Results: Among 1,068 adults recruited 963 (90.2%) were between 18 and 64 years-old, 682 (63.9%) women. 176 (16.5%) reported symptoms indicative of SARS-CoV-2 infection occurring in previous three months. Nine persons tested positive for IgG: crude seroprevalence: 0.84%, (95% CI: 0.33%-1.59%), weighted seroprevalence: 0.94% (95% CI: 0.37%-1.95%), weighted and adjusted for test accuracy: 1.02% (95% CI: 0.38%-2.18%). The seroprevalence estimates translate into 7,200 to 8,800 infections among adult residents of Tbilisi, which is at least 20 times higher than the number of confirmed cases. Conclusions: Low seroprevalence confirms that Georgia successfully contained spread of SARS-CoV-2 during the first wave of pandemic. Findings also suggest that undocumented cases due to asymptomatic or very mild disease account for majority of infections. Given that asymptomatic persons can potentially spread the virus, test and isolate approach should be further expanded to control the epidemic.","Tsertsvadze, T.; Gatserelia, L.; Mirziashvili, M.; Dvali, N.; Abutidze, A.; Metchurtchlishvili, R.; del Rio, C.; Chkhartishvili, N.","https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20195024v1?rss=1,2020-09-18,2020-09-18,,True
42,Early Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial,"Background: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression. Methods: Open-label, single-center, randomized clinical trial performed in an academic center in Santiago, Chile from May 10, 2020, to July 18, 2020, with final follow-up August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptoms onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted in immediate CP (early plasma group) versus no CP unless developing pre-specified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days or death. Key secondary outcomes included: time to respiratory failure, days of mechanical ventilation, hospital length-of-stay, mortality at 30 days, and SARS-CoV-2 RT-PCR clearance rate. Results: Of 58 randomized patients (mean age, 65.8 years, 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We found no benefit in the primary outcome (32.1% vs 33.3%, OR 0.95, 95% CI 0.32-2.84, p>0.99) in the early versus deferred CP group. In-hospital mortality rate was 17.9% vs 6.7% (OR 3.04, 95% CI 0.54-17.2, p=0.25), mechanical ventilation 17.9% vs 6.7% (OR 3.04, 95% CI 0.54-17.2, p=0.25), and prolonged hospitalization 21.4% vs 30% (OR 0.64, 95%CI, 0.19-2.1, p=0.55) in early versus deferred CP group, respectively. Viral clearance rate on day 3 (26% vs 8%, p=0.20) and day 7 (38% vs 19%, p=0.37) did not differ between groups. Two patients experienced serious adverse events within 6 or less hours after plasma transfusion. Conclusion: Immediate addition of CP therapy in early stages of COVID-19 -compared to its use only in case of patient deterioration- did not confer benefits in mortality, length of hospitalization or mechanical ventilation requirement.","Balcells, M. E.; Rojas, L.; Le Corre, N.; Martinez-Valdebenito, C.; Ceballos, M. E.; Ferres, M.; Chang, M.; Vizcaya, C.; Mondaca, S.; Huete, A.; Castro, R.; Sarmiento, M.; Villarroel, L.; Pizarro, A.; Ross, P.; Santander, J.; Lara, B.; Ferrada, M.; Vargas-Salas, S.; Beltran-Pavez, C.; Soto-Rifo, R.; Valiente-Echeverria, F.; Caglevic, C.; Mahave, M.; Selman, C.; Gazitua, R.; Briones, J. L.; Villarroel-Espindola, F.; Balmaceda, C.; Espinoza, M. A.; Pereira, J.; Nervi, B.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1?rss=1,2020-09-18,2020-09-18,,True
43,Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care,"Introduction A significant proportion of patients with Coronavirus Disease-19 (COVID-19) have hypertension and are treated with renin-angiotensin system (RAS) inhibitors, namely angiotensin-converting enzyme I inhibitors (ACE inhibitors) or angiotensin II type-1 receptor blockers (ARBs). These medications have been postulated to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The objective of this study was to assess a possible association between prescription of RAS inhibitors and the incidence of COVID-19 and all-cause mortality. Methods We conducted a propensity-score matched cohort study to assess the incidence of COVID-19 among patients with hypertension who were prescribed ACE inhibitors or ARBs compared to patients treated with calcium channel blockers (CCBs) in a large UK-based primary care database (The Health Improvement Network). We estimated crude incidence rates for confirmed/suspected COVID-19 among those prescribed ACE inhibitors, ARBs and CCBs. We used a Cox proportional hazards model to produce adjusted hazard ratios for COVID-19 comparing patients prescribed ACE inhibitors or ARBs to those prescribed CCBs. We further assessed all-cause mortality as a secondary outcome and a composite of accidents, trauma or fractures as a negative control outcome to assess for residual confounding. Results In the propensity score matched analysis, 83 of 18,895 users (0.44%) of ACE inhibitors developed COVID-19 over 8,923 person-years, an incidence rate of 9.3 per 1000 person-years. 85 of 18,895 (0.45%) users of CCBs developed COVID-19 over 8,932 person-years, an incidence rate of 9.5 per 1000 person-years. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ACE inhibitors compared to CCBs was 0.92 (95% CI 0.68 to 1.26). 79 out of 10,623 users (0.74%) of ARBs developed COVID-19 over 5010 person-years, an incidence rate of 15.8 per 1000 person-years, compared to 11.6 per 1000 person-years among users of CCBs. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ARBs compared to CCBs was 1.38 (95% CI 0.98 to 1.95). There were no significant associations between use of ACE inhibitors or ARBs and all-cause mortality, compared to use of CCBs. We found no evidence of significant residual confounding with the negative control analysis. Conclusion Current use of ACE inhibitors was not associated with the risk of suspected or confirmed COVID-19 whereas use of ARBs was associated with a statistically non-significant 38% relative increase in risk compared to use of CCBs. However, no significant associations were observed between prescription of either ACE inhibitors or ARBs and all-cause mortality during the peak of the pandemic.","Haroon, S.; Subramanian, A.; Cooper, J.; Anand, A.; Gokhale, K.; Byne, N.; Dhalla, S.; Acosta-Mena, D.; Taverner, T.; Okoth, K.; Wang, J.; Chandan, J. S.; Sainsbury, C.; Zemedikun, D. T.; Thomas, G. N.; Parekh, D.; Marshall, T.; Sapey, E.; Adderley, N. J.; Nirantharakumar, K.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196469v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196469v1?rss=1,2020-09-18,2020-09-18,,True
44,COPD in the time of COVID-19: An analysis of acute exacerbations and reported behavioural changes in patients with COPD,"ABSTRACT Introduction: The impact of the SARS-CoV-2 pandemic, and lockdown measures, on acute exacerbations of COPD (AECOPD) is unknown. We aimed to evaluate the change in AECOPD treatment frequency during the first six weeks of lockdown in the UK compared with 2019 and assess changes in self-reported behaviour and well-being. Methods: In this observational study patients with established COPD were recruited. Exacerbation frequency was measured in the first six weeks of COVID lockdown and compared with the same period in 2019 using electronic health records. A telephone survey was used to assess changes in anxiety, inhaler adherence, physical activity, shopping and visitor behaviour during the pre-lockdown and lockdown periods compared to normal. Results: 160 participants were recruited (mean [SD] age 67.3 [8.1] years, 88 [55%] male, FEV1 34.3 [13] % predicted) and 140 [88%] reported at least one AECOPD in the previous year. Significantly more community treated exacerbations were observed in 2020 compared with 2019 (126 vs 99, p=0.026). The increase was as a result of multiple courses of treatment, with a similar proportion of patients receiving at least one course (34.4% vs 33.8%). During 'lockdown' participants reported significantly increased anxiety, adherence to their preventative inhalers, and good adherence to shielding advice (all p<0.001). A significant reduction in self-reported physical activity and visitors was reported (both p<0.001). Discussion: Treatment for AECOPD events increased during the first six weeks of the SARS-CoV-2 pandemic in the UK compared to 2019. This was associated with increased symptoms of anxiety and significant behavioural change.","McAULEY, H. J. C.; Hadley, K.; Elneima, O.; Brightline, C. E.; Evans, R.; Steiner, M. C.; Greening, N.","https://www.medrxiv.org/content/10.1101/2020.09.18.20197202v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20197202v1?rss=1,2020-09-18,2020-09-18,,True
45,THE REMOTE ANALYSIS OF BREATH SOUND IN COVID-19 PATIENTS: A SERIES OF CLINICAL CASES,"Background: Respiratory sounds have been recognized as a possible indicator of behavior and health. Computer analysis of these sounds can indicate of characteristic sound changes caused by COVID-19 and can be used for diagnosis of this illness. Purpose: The communication aim is development of fast remote computer-assistance diagnosis of COVID-19, based on analysis of respiratory sounds. Materials and Methods: Fast Fourier transform (FFT) was applied for analyses of respiratory sounds recorded near the mouth of 9 COVID-19 patients and 4 healthy volunteers. Sampling rate was 48 kHz. Results: Comparing of FFT spectrums of the respiratory sounds of the patients and volunteers we proposed numerical healthy-ill criterions. Conclusions: The proposed computer method, based on analysis of the FFT spectrums of respiratory sounds of the patients and volunteers, allows one to automatically diagnose COVID-19 with sufficiently high diagnostic values. This method can be applied at development of noninvasive self-testing kits for COVID-19.","Furman, E. G.; Charushin, A.; Eirikh, E.; Malinin, S.; Sheludko, V.; Sokolovsky, V.; Furman, G.","https://www.medrxiv.org/content/10.1101/2020.09.16.20195289v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195289v1?rss=1,2020-09-18,2020-09-18,,True
46,"Meta-analysis of the clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22 August 2020","We reviewed the clinical performance of SARS-CoV-2 nucleic acid, viral antigen and antibody tests based on 94739 test results from 157 published studies and 20205 new test results from 12 EU/EEA Member States. Pooling the results and considering only results with 95% confidence interval width [&le;]5%, we found 4 nucleic acid tests, among which 1 point of care test, and 3 antibody tests with a clinical sensitivity [&le;]95% for at least one target population (hospitalised, mild or asymptomatic, or unknown). Analogously, 9 nucleic acid tests and 25 antibody tests, among which 12 point of care tests, had a clinical specificity of [&le;]98%. Three antibody tests achieved both thresholds. Evidence for nucleic acid and antigen point of care tests remains scarce at present, and sensitivity varied substantially. Study heterogeneity was low for 8/14 (57.1%) sensitivity and 68/84 (81.0%) specificity results with confidence interval width [&le;]5%, and lower for nucleic acid tests than antibody tests. Manufacturer reported clinical performance was significantly higher than independently assessed in 11/32 (34.4%) and 4/34 (11.8%) cases for sensitivity and specificity respectively, indicating a need for improvement in this area. Continuous monitoring of clinical performance within more clearly defined target populations is needed.","Van Walle, I.; Leitmeyer, K.; Broberg, E. K.; The European COVID-19 microbiological laboratories group,","https://www.medrxiv.org/content/10.1101/2020.09.16.20195917v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195917v1?rss=1,2020-09-18,2020-09-18,,True
47,Ranking the relative importance of COVID-19 immunisation strategies: a survey of expert stakeholders in Canada,"Background: In the face of anticipated limited COVID-19 vaccine supply necessitating the vaccination of certain groups earlier than others, the assessment of values and preferences of stakeholders is an important component of an ethically sound vaccine prioritisation framework. Objective: To establish a preliminary expert stakeholder perspective on the relative importance of pandemic immunisation strategies for different COVID-19 pandemic scenarios at the time of initial COVID-19 vaccine availability. Methods: A survey was conducted by an email process from July 22 to August 14, 2020. Stakeholders included clinical and public health expert groups, provincial and territorial committees and national Indigenous groups, patient and community advocacy representatives and experts, health professional associations, and federal government departments in Canada. Survey results were analysed using descriptive statistics. Results: Of 156 stakeholders contacted, 74 surveys were completed for a participation rate of 47.4%. During an anticipated period of initial vaccine scarcity for all pandemic scenarios, stakeholders generally considered the most important immunisation strategy to be protecting those who are most vulnerable to severe illness and death from COVID-19. This was followed in importance by the strategies to protect healthcare capacity, and to minimise transmission of COVID-19. In this supply constrained context, an immunisation strategy to protect critical infrastructure was considered the least important. Conclusion: The findings of this study provide a timely, preliminary Canadian expert perspective on priority COVID-19 pandemic immunisation strategies to guide early public health planning for an eventual COVID-19 immunisation program. These results fill a gap in the literature and could help advisory groups around the world in their assessment of values and preferences for ethical guidelines for COVID-19 vaccine allocation.","Zhao, L.; Ismail, S. J.; Tunis, M. C.","https://www.medrxiv.org/content/10.1101/2020.09.16.20196295v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20196295v1?rss=1,2020-09-18,2020-09-18,,True
48,Disparities in COVID-19 Related Mortality in U.S. Prisons and the General Population,"We provide an analysis of COVID-19 mortality data to assess the potential magnitude of COVID-19 among prison residents. Data were pooled from Covid Prison Project and multiple publicly available national and state level sources. Data analyses consisted of standard epidemiologic and demographic estimates. A single case study was included to generate a more in-depth and multi-faceted understanding of COVID-19 mortality in prisons. The increase in crude COVID-19 mortality rates for the prison population has outpaced the rates for the general population. People in prison experienced a significantly higher mortality burden compared to the general population (standardized mortality ratio (SMR) = 2.75; 95% confidence interval = 2.54, 2.96). For a handful of states (n = 5), these disparities were more extreme, with SMRs ranging from 5.55 to 10.56. Four states reported COVID-19 related death counts that are more than 50% of expected deaths from all-causes in a calendar year. The case study suggested there was also variation in mortality among units within prison systems, with geriatric facilities potentially at highest risk. Understanding the dynamic trends in COVID-19 mortality in prisons as they move in and out of hotspot status is critical.","Nowotny, K. M.; Cloud, D.; Wurcel, A. G.; Brinkley-Rubinstein, L.","https://www.medrxiv.org/content/10.1101/2020.09.17.20183392v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20183392v1?rss=1,2020-09-18,2020-09-18,,True
49,RPA-Based Method For The Detection Of SARS-CoV2,"Background: Coronavirus disease 2019 (COVID-19) is a highly infectious disease with significant mortality, morbidity, and far-reaching economic and social disruptions. Testing is key in the fight against COVID-19 disease. The gold standard for COVID-19 testing is the reverse transcription polymerase chain reaction (RT-PCR) test. RT-PCR requires highly specialized, expensive, and advanced bulky equipment that is difficult to use in the field or in a point of care setting. There is need for a simpler, inexpensive, convenient, portable and accurate test. Our aims were to: (i) design primer-probe pairs for use in isothermal amplification of the S1, ORF3 and ORF8 regions of the SARS-CoV2 virus; (ii) optimize the recombinase polymerase amplification (RPA) assay for the isothermal amplification of the named SARS-COV2 regions; (iii) detect amplification products on a lateral flow device. and (ii) perform a pilot field validation of RPA on RNA extracted from nasopharyngeal swabs. Results: Assay validation was done at the National Reference Lab (NRL) at the Rwanda Biomedical Center (RBC) in Rwanda. Results were compared to an established, WHO-approved rRT-PCR laboratory protocol. The assay provides a faster and cheaper alternative to rRT-PCR with 100% sensitivity, 93% specificity, and positive and negative predictive agreements of 100% and 93% respectively. Conclusion: To the best of our knowledge, this is the first in-field and comparative laboratory validation of RPA for COVID-19 disease in low resource settings. Further standardization will be required for deployment of the RPA assay in field settings. Keywords: Recombinase Polymerase Amplification, COVID-19","Nassir, A. A.; Baptiste, M. J.; Mwikarago, I.; Habimana, M. R.; Ndinkabandi, J.; Murangwa, A.; Nyatanyi, T.; Muvunyi, C. M.; Nsanzimana, S.; Leon, M.; Musanabaganwa, C.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196402v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196402v1?rss=1,2020-09-18,2020-09-18,,True
50,"Variation of SARS-CoV-2 viral loads by sample type, disease severity and time: a systematic review","Background. To describe whether SARS-CoV-2 viral loads (VLs) and cycle thresholds (CTs) vary by sample type, disease severity and symptoms duration. Methods. Systematic searches were conducted in MEDLINE, EMBASE, BioRxiv and MedRxiv. Studies reporting individual SARS-CoV-2 VLs and/or CT values from biological samples. Paired reviewers independently screened potentially eligible articles. CT values and VLs distributions were described by sample type, disease severity and time from symptom onset. Differences between groups were examined using Kruskal-Wallis and Dunn's tests (post-hoc test). The risk of bias was assessed using the Joanna Briggs Critical Appraisal Tools. Results. 14 studies reported CT values, 8 VLs and 2 CTs and VLs, resulting in 432 VL and 873 CT data points. VLs were higher in saliva and sputum (medians 4.7x108 and 6.5x104 genomes per ml, respectively) than in nasopharyngeal and oropharyngeal swabs (medians 1.7x102 and 4.8x103). Combined naso/oropharyngeal swabs had lower CT values (i.e. higher VLs) than single site samples (p=<0.0001). CT values were also lower in asymptomatic individuals and patients with severe COVID-19 (median CT 30 for both) than among patients with moderate and mild symptoms (31.4 and 31.3, respectively). Stool samples were reported positive for a longer period than other specimens. Conclusion. VLs are higher in saliva and sputum and in individuals who are asymptomatic of with severe COVID-19. Diagnostic testing strategies should consider that VLs vary by sample type, disease severity and time since symptoms onset.","Edwards, T.; Santos, V. S.; Wilson, A. L.; Cubas-Atienzar, A. I.; Kontogianni, K.; Williams, C. T.; Adams, E. R.; Cuevas, L. E.","https://www.medrxiv.org/content/10.1101/2020.09.16.20195982v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195982v1?rss=1,2020-09-18,2020-09-18,,True
51,Investigating the implications of COVID-19 for the rural and remote population of Northern Ontario using a mathematical model,"Background: COVID-19 has the potential to disproportionately affect the rural, remote, and Indigenous populations who typically have a worse health status and live in substandard housing, often with overcrowding. Our aim is to investigate the potential effect of COVID-19 on intensive care unit (ICU) resources and mortality in northwestern Ontario. Methods: This study was conducted in northwestern Ontario which has a population of 230,000. A set of differential equations were used to represent a modified Susceptible-Infectious-Recovered (SIR) model with urban and rural hospital resources (i.e., ICU and hospital beds). Rural patients requiring ICU care flowed into the urban ICU. Sensitivity analyses were used to investigate the effect of poorer health status (i.e., increased hospital admission, ICU admission, and mortality) and overcrowding (i.e., increased contact rate) in the rural population as compared to the urban population. Physical distancing within the urban population was modelled as a decreased contact rate. Results: At the highest contact rate, the peak in daily active cases, ICU bed requirements and mortality was higher and occurred earlier than lower contact rates. The urban population with a lower contact rate and baseline health status had a lower predicted prevalence of active cases and lower mortality than the rural population. Interpretation: An increased contact rate and worse health status in the rural population will likely increase the required ICU resources and mortality as compared to the urban population. Rural populations will likely be affected disproportionately more than urban populations.","Savage, D.; Fisher, A.; Choudhury, S.; Ohle, R.; Strasser, R.; Orkin, A.; Mago, V.","https://www.medrxiv.org/content/10.1101/2020.09.17.20196949v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20196949v1?rss=1,2020-09-18,2020-09-18,,True
52,Association between corticosteroids and intubation or death among patients with COVID-19 pneumonia in non-ICU settings: an observational study using of real-world data from 51 hospitals in France and Luxembourg,"Objective To assess the effectiveness of corticosteroids on outcomes of patients with mild COVID-19 pneumonia. Methods We used routine care data from 51 hospitals in France and Luxembourg to assess the effectiveness of corticosteroids at 0.8 mg/kg/day eq. prednisone (CTC group) vs standard of care (no-CTC group) among patients [&le;] 80 years old with COVID-19 pneumonia requiring oxygen without mechanical ventilation. The primary outcome was intubation or death at Day 28. Baseline characteristics of patients were balanced using propensity score inverse probability of treatment weighting. Results Among the 891 patients included in the analysis, 203 were assigned to the CTC group. At day 28, corticosteroids did not reduce the rate of the primary outcome (wHR 0.92, 95% CI 0.61 to 1.39) nor the cumulative death rate (wHR 1.03, 95% CI 0.54 to 1.98). Corticosteroids significantly reduced the rate of the primary outcome for patients requiring oxygen [&ge;] at 3L/min (wHR 0.50, 95% CI 0.30 to 0.85) or C-Reactive Protein (CRP) [&ge;] 100mg/L (wHR 0.44, 95%CI 0.23 to 0.85). We found a higher number of hyperglycaemia events among patients who received corticosteroids, but number of infections were similar across the two groups. Conclusions We found no association between the use of corticosteroids and intubation or death in the broad population of patients [&le;]80 years old with COVID-19 hospitalized in non-ICU settings. However, the treatment was beneficial for patients with [&ge;] 3L/min oxygen or CRP [&ge;] 100mg/L at baseline. These data support the need to confirm the right timing of corticosteroids for patients with mild COVID.","Tran, V.-T.; Mahevas, M.; Bani Sadr, F.; Robineau, O.; Perpoint, T.; Perrodeau, E.; Gallay, L.; Ravaud, P.; Goehringer, F.; Lescure, X.; COCORICO,","https://www.medrxiv.org/content/10.1101/2020.09.16.20195750v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195750v1?rss=1,2020-09-18,2020-09-18,,True
53,Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study.,"Aim To estimate the seroprevalence of SARS-CoV-2 infection in May-June 2020 after the lockdown in adults living in three regions in France and to identify the associated risk factors. Methods Participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE), two regions with high rate of COVID-19, or in the Nouvelle-Aquitaine (NA), with a low rate, were asked to take a dried-blood spot (DBS) for anti-SARS-CoV-2 antibodies assessment. The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). The secondary outcomes were a positive ELISA IgG against the nucleocapsid protein (ELISA-NP), anti-SARS-CoV-2 neutralizing antibodies titers >=40 (SN), and predicted positivity obtained from a multiple imputation model (MI). Prevalence estimates were adjusted using sampling weights and post-stratification methods. Findings Between May 4, 2020 and June 23, 2020, 16,000 participants were asked to provide DBS, and 14,628 were included in the analysis, 983 with a positive ELISA-S, 511 with a positive ELISA-NP, 424 with SN>=40 and 941 (Standard Deviation=31) with a positive MI. Adjusted estimates of seroprevalence (positive ELISA-S) were 10.0% (95%CI 9.1%;10.9%) in IDF, 9.0% (95%CI 7.7%; 10.2%) in GE and 3.1% (95%CI 2.4%; 3.7%), in NA. The adjusted prevalence of positive ELISA-NP, SN and MI were 5.7%, 5.0% and 10.0% in IDF, 6.0%, 4.3% and 8.6% in GE, and 0.6%, 1.3% and 2.5% in NA, respectively. A higher seroprevalence was observed in younger participants and when at least one child or adolescent lived in the same household. A lower seroprevalence was observed in smokers compared to non-smokers. Interpretation At the end of the lockdown the prevalence of anti-SARS-CoV-2 IgG or neutralizing antibodies remained low in the French adult population, even in regions with high reported rates of COVID-19.","Carrat, F.; de Lamballerie, X.; Rahib, D.; Blanche, H.; Lapidus, N.; Artaud, F.; Kab, S.; Renuy, A.; Szabo de Edelenyi, F.; Meyer, L.; Lydie, N.; Charles, M.-A.; Ancel, P.-Y.; Jusot, F.; Rouquette, A.; Priet, S.; Saba Villaroel, P. M.; Fourie, T.; Lusivika-Nzinga, C.; Nicol, J.; Legot, S.; Druesne-Pecollo, N.; Essedik, Y.; Lai, C.; Gagliolo, J.-M.; Deleuze, J.-F.; Bajos, N.; Severi, G.; Touvier, M.; Zins, M.","https://www.medrxiv.org/content/10.1101/2020.09.16.20195693v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.16.20195693v1?rss=1,2020-09-18,2020-09-18,,True
54,How do the general population behave with facemasks to prevent COVID-19 in the community?,"IMPORTANCE The appropriate use of facemasks, recommended or mandated by authorities, is critical to protect the community and prevent the spread of COVID-19. OBJECTIVE To evaluate the frequency and quality of facemask use in general populations of different socio-spatial backgrounds. DESIGN A multi-site observational study carried out from 25 June 2020 to 21 July 2020. SETTING The observations were carried out in 43 different locations in a region in the west of France, representing various areas: rural and urban, indoor and outdoor, and in areas where masks were mandated or not. An observer was positioned at a predetermined place, facing a landmark, and collected information about the use of facemasks and socio-demographic data. PARTICIPANTS All individual passing between the observer and the landmark were included. EXPOSURE The observer collected information on whether a mask was worn, the type of mask used, the quality of the positioning, gender, and the age category of each individual. MAIN OUTCOMES AND MEASURES The main outcomes were the use of a facemask and the quality of the positioning. Factors associated with these outcomes were identified. RESULTS A total of 3354 observations were recorded. A facemask was worn by 56.4% (n=1892) of individuals, varying from 49% (n=1359) in non-mandatory areas and 91.7% (n=533) in mandatory areas, including surgical facemasks (56.8%, n=1075) and cloth masks (43.2%, n=817). The facemask was correctly positioned in 75.2% (n=1422) of cases. The factors independently associated with wearing a facemask were being indoors (adjusted odds ratio [aOR], 0.37; 95% confidence interval [CI], 0.31-0.44), being in a mandatory area (aOR, 0.14; 95%CI, 0.10-0.20), female gender (aOR, 0.57; 95%CI, 0.49-0.66), and age >40 years (aOR, 0.54; 95%CI, 0.46-0.63). The factors independently associated with correct mask position were rural location (aOR, 0.76; 95%CI, 0.97-0.98), being in an indoor area (aOR, 0.49; 95%CI, 0.38-0.65), use of a cloth mask (aOR, 0.65; 95%CI, 0.52-0.81), and age >40 years (aOR, 0.61; 95%CI 0.49-0.76). CONCLUSIONS AND RELEVANCE Information campaigns should promote the use of cloth masks. Young people in general and men in particular are the priority targets. Simplifying the rules to require universal mandatory masking seems to be the best approach for health authorities.","DESCHANVRES, C.; HAUDEBOURG, T.; PEIFFER-SMADJA, N.; BLANCKAERT, K.; BOUTOILLE, D.; LUCET, J.-C.; BIRGAND, G.","https://www.medrxiv.org/content/10.1101/2020.09.18.20195669v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.18.20195669v1?rss=1,2020-09-18,2020-09-18,,True
55,High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in healthcare workers: results of the CoV-CONTACT prospective cohort,"Objective: We aimed to estimate the risk of infection in Healthcare workers (HCWs) following a high-risk exposure without personal protective equipment (PPE). Methods: We conducted a prospective cohort in HCWs who had a high-risk exposure to SARS-CoV-2-infected subject without PPE. Daily symptoms were self-reported for 30 days, nasopharyngeal swabs for SARS-CoV-2 RT-PCR were performed at inclusion and at days 3, 5, 7 and 12, SARS-CoV-2 serology was assessed at inclusion and at day 30. Confirmed infection was defined by positive RT-PCR or seroconversion, and possible infection by one general and one specific symptom for two consecutive days. Results: Between February 5th and May 30th, 2020, 154 HCWs were enrolled within 14 days following one high-risk exposure to either a hospital patient (70/154; 46.1%) and/or a colleague (95/154; 62.5%). At day 30, 25.0% had a confirmed infection (37/148; 95%CI, 18.4%; 32.9%), and 43.9% (65/148; 95%CI, 35.9%; 52.3%) had a confirmed or possible infection. Factors independently associated with confirmed or possible SARS-CoV-2 infection were being a pharmacist or administrative assistant rather than being from medical staff (adjusted OR (aOR)=3.8, CI95%=1.3;11.2, p=0.01), and exposure to a SARS-CoV-2-infected patient rather than exposure to a SARS-CoV-2-infected colleague (aOR=2.6, CI95%=1.2;5.9, p=0.02). Among the 26 HCWs with a SARS-CoV-2-positive nasopharyngeal swab, 7 (26.9%) had no symptom at the time of the RT-PCR positivity. Conclusions: The proportion of HCWs with confirmed or possible SARS-CoV-2 infection was high. There were less occurrences of high-risk exposure with patients than with colleagues, but those were associated with an increased risk of infection.","Tubiana, S.; Burdet, C.; Houhou, N.; Thy, M.; Manchon, P.; Blanquart, F.; Charpentier, C.; Guedj, J.; Alavoine, L.; Behillil, S.; Leclercq, A.; Lucet, J.-C.; Yazdanpanah, Y.; Attia, M.; Demeret, C.; Rose, T.; Bielicki, J. A.; Bruijning-Verhagen, P.; Goossens, H.; Descamps, D.; van der Werf, S.; Lina, B.; Duval, X.","https://www.medrxiv.org/content/10.1101/2020.09.17.20194860v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.09.17.20194860v1?rss=1,2020-09-18,2020-09-18,,True
56,Identification of novel antiviral drug combinations in vitro and tracking their development,"Combination therapies have become a standard for the treatment for HIV and HCV infections. They are advantageous over monotherapies due to better efficacy and reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify several new synergistic combinations against emerging and re-emerging viral infections in vitro. We observed synergistic activity of nelfinavir with investigational drug EIDD-2801 and convalescent serum against SARS-CoV-2 infection in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of vemurafenib combination with emetine, homoharringtonine, gemcitabine, or obatoclax against echovirus 1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar and niclosamide were synergistic against HCV infection in hepatocyte derived Huh-7.5 cells, whereas combinations of monensin with lamivudine and tenofovir were synergistic against HIV-1 infection in human cervical TZM-bl cells. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status. Overall, the development of combinational therapies could have a global impact improving the preparedness and protection of the general population from emerging and re-emerging viral threats.","Ianevski, A.; Yao, R.; Biza, S.; Zusinaite, E.; Mannik, A.; Kivi, G.; Planken, A.; Kurg, K.; Tombak, E.-M.; Ustav, M.; Shtaida, N.; Kulesskiy, E.; Jo, E.; Yang, J.; Lysvand, H.; Loseth, K.; Oksenych, V.; Aas, P. A.; Tenson, T.; Vitkauskiene, A.; Windisch, M. P.; Fenstad, M. H.; Nordbo, S. A.; Ustav, M.; Bjoras, M.; Kainov, D. E.","https://www.biorxiv.org/content/10.1101/2020.09.17.299933v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.299933v1?rss=1,2020-09-17,2020-09-17,,False
57,A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture,"Soluble forms of ACE2 have recently been shown to inhibit SARS-CoV-2 infection. We report on an improved soluble ACE2, termed a ""microbody"" in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain. The protein is smaller than previously described ACE2-Ig Fc fusion proteins and contains an H345A mutation in the ACE2 catalytic active site that inactivates the enzyme without reducing its affinity for the SARS-CoV-2 spike. The disulfide-bonded ACE2 microbody protein inhibited entry of lentiviral SARS-CoV-2 spike protein pseudotyped virus and live SARS-CoV-2 with a potency 10-fold higher than unmodified soluble ACE2 and was active after initial virus binding to the cell. The ACE2 microbody inhibited the entry of ACE2-specific {beta} coronaviruses and viruses with the high infectivity variant D614G spike. The ACE2 microbody may be a valuable therapeutic for COVID-19 that is active against SARS-CoV-2 variants and future coronaviruses that may arise.","Tada, T.; Fan, C.; Kaur, R.; Stapleford, K. A.; Gristick, H.; Nimigean, C.; Landau, N. R.","https://www.biorxiv.org/content/10.1101/2020.09.16.300319v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300319v1?rss=1,2020-09-17,2020-09-17,,False
58,Comparison of Rhesus and Cynomolgus macaques as an authentic model for COVID-19.,"A novel coronavirus, SARS-CoV-2, has been identified as the causative agent of the current COVID-19 pandemic. Animal models, and in particular non-human primates, are essential to understand the pathogenesis of emerging diseases and to the safety and efficacy of novel vaccines and therapeutics. Here, we show that SARS-CoV-2 replicates in the upper and lower respiratory tract and causes pulmonary lesions in both rhesus and cynomolgus macaques, resembling the mild clinical cases of COVID-19 in humans. Immune responses against SARS-CoV-2 were also similar in both species and equivalent to those reported in milder infections and convalescent human patients. Importantly, we have devised a new method for lung histopathology scoring that will provide a metric to enable clearer decision making for this key endpoint. In contrast to prior publications, in which rhesus are accepted to be the optimal study species, we provide convincing evidence that both macaque species authentically represent mild to moderate forms of COVID-19 observed in the majority of the human population and both species should be used to evaluate the safety and efficacy of novel and repurposed interventions against SARS-CoV-2. Accessing cynomolgus macaques will greatly alleviate the pressures on current rhesus stocks.","Salguero, F. J.; White, A. D.; Slack, G. S.; Fotheringham, S. A.; Bewley, K. R.; Gooch, K. E.; Longet, S.; Humphries, H. E.; Watson, R. J.; Hunter, L.; Ryan, K. A.; Hall, Y.; Sibley, L.; Sarfas, C.; Allen, L.; Aram, M.; Brunt, E.; Brown, P.; Buttigieg, K. R.; Cavell, B. E.; Cobb, R.; Coombes, N. S.; Daykin-Pont, O.; Elmore, M. J.; Gkolfinos, K.; Godwin, K. J.; Gouriet, J.; Halkerston, R.; Harris, D. J.; Hender, T.; Ho, C. M. K.; Kennard, C. L.; Knott, D.; Leung, S.; Lucas, V.; Mabbutt, A.; Morrison, A. L.; Ngabo, D.; Paterson, J.; Penn, E. J.; Pullan, S.; Taylor, I.; Tipton, T.; Thomas, S.; Tree, J. A.; Turner, C.; Wand, N.; Wiblin, N. R.; Charlton, S.; Hallis, B.; Pearson, G.; Rayner, E. L.; Nicholson, A. G.; Funnell, S. G.; Dennis, M. J.; Gleeson, F. V.; Sharpe, S.; Carroll, M. W.","https://www.biorxiv.org/content/10.1101/2020.09.17.301093v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.301093v1?rss=1,2020-09-17,2020-09-17,,False
59,Distinct SARS-CoV-2 Antibody Reactivity Patterns in Coronavirus Convalescent Plasma Revealed by a Coronavirus Antigen Microarray,"A coronavirus antigen microarray (COVAM) was constructed containing 11 SARS-CoV-2, 5 SARS-1, 5 MERS, and 12 seasonal coronavirus recombinant proteins. The array is designed to measure immunoglobulin isotype and subtype levels in serum or plasma samples against each of the individual antigens printed on the array. We probed the COVAM with COVID-19 convalescent plasma (CCP) collected from 99 donors who recovered from a PCR+ confirmed SARS-CoV-2 infection. The results were analyzed using two computational approaches, a generalized linear model (glm) and Random Forest (RF) prediction model, to classify individual specimens as either Reactive or Non-Reactive against the SARS-CoV-2 antigens. A training set of 88 pre-COVID-19 specimens (PreCoV) collected in August 2019 and102 positive specimens from SARS-CoV-2 PCR+ confirmed COVID-19 cases was used for these analyses. Results compared with an FDA emergency use authorized (EUA) SARS-CoV2 S1-based total Ig chemiluminescence immunoassay (Ortho Clinical Diagnostics VITROS(R) Anti-SARS-CoV-2 Total, CoV2T) and with a SARS-CoV-2 S1-S2 spike-based pseudovirus micro neutralization assay (SARS-CoV-2 reporter viral particle neutralization titration (RVPNT) showed high concordance between the 3 assays. Three CCP specimens that were negative by the VITROS CoV2T immunoassay were also negative by both COVAM and the RVPNT assay. Concordance between VITROS CoV2T and COVAM was 96%, VITROS CoV2T and RVPNT 93%, and RVPNT and COVAM 95%. The discordances were all weakly reactive samples near the cutoff threshold of the VITROS CoV2T immunoassay. The multiplex COVAM allows CCP to be grouped according to antibody reactivity patterns against 11 SARS-CoV-2 antigens. Unsupervised K-means analysis, via the gap statistics, as well as hierarchical clustering analysis revealed 3 main clusters with distinct reactivity intensities and patterns. These patterns were not recapitulated by adjusting the VITROS CoV2T or RVPNT assay thresholds. Plasma classified according to these reactivity patterns may be better associated with CCP treatment efficacy than antibody levels alone. The use of a SARS-CoV-2 antigen array may be useful to qualify CCP for administration as a treatment for acute COVID-19 and to interrogate vaccine immunogenicity and performance in preclinical and clinical studies to understand and recapitulate antibody responses associated with protection from infection and disease.","Ramiro de Assis, R.; Jain, A.; Nakajima, R.; Jasinskas, A.; Khan, S.; Dumont, L. J.; Kelly, K.; Simmons, G.; Stone, M.; Di Germanio, C.; Busch, M. P.; Felgner, P. L.","https://www.biorxiv.org/content/10.1101/2020.09.16.300871v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300871v1?rss=1,2020-09-17,2020-09-17,,False
60,"Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis","To date, the Covid-19 pandemic affected more than 18 million individuals and caused more than 690, 000 deaths. Its clinical expression is pleiomorphic and severity is related to age and comorbidities such as diabetes and hypertension. The pathophysiology of the disease relies on aberrant activation of immune system and lymphopenia that has been recognized as a prognosis marker. We wondered if the myeloid compartment was affected in Covid-19 and if monocytes and macrophages could be infected by SARS-CoV-2. We show here that SARS-CoV-2 efficiently infects monocytes and macrophages without any cytopathic effect. Infection was associated with the secretion of immunoregulatory cytokines (IL-6, IL-10, TGF-{beta}) and the induction of a macrophagic specific transcriptional program characterized by the upregulation of M2-type molecules. In addition, we found that in vitro macrophage polarization did not account for the permissivity to SARS-CoV-2, since M1-and M2-type macrophages were similarly infected. Finally, in a cohort of 76 Covid-19 patients ranging from mild to severe clinical expression, all circulating monocyte subsets were decreased, likely related to massive emigration into tissues. Monocytes from Covid-19 patients exhibited decreased expression of HLA-DR and increased expression of CD163, irrespective of the clinical status. Hence, SARS-CoV-2 drives circulating monocytes and macrophages inducing immunoparalysis of the host for the benefit of Covid-19 disease progression.","Boumaza, A.; Gay, L.; Mezouar, S.; Diallo, A. B.; Michel, M.; Desnues, B.; Raoult, D.; LA SCOLA, B.; Halfon, P.; Vitte, J.; Olive, D.; Mege, J.-L.","https://www.biorxiv.org/content/10.1101/2020.09.17.300996v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.300996v1?rss=1,2020-09-17,2020-09-17,,False
61,Mutational signatures in countries affected by SARS-CoV-2: Implications in host-pathogen interactome,"We are in the midst of the third severe coronavirus outbreak caused by SARS-CoV-2 with unprecedented health and socio-economic consequences due to the COVID-19. Globally, the major thrust of scientific efforts has shifted to the design of potent vaccine and anti-viral candidates. Earlier genome analyses have shown global dominance of some mutations purportedly indicative of similar infectivity and transmissibility of SARS-CoV-2 worldwide. Using high-quality large dataset of 25k whole-genome sequences, we show emergence of new cluster of mutations as result of geographic evolution of SARS-CoV-2 in local population ([&ge;]10%) of different nations. Using statistical analysis, we observe that these mutations have either significantly co-occurred in globally dominant strains or have shown mutual exclusivity in other cases. These mutations potentially modulate structural stability of proteins, some of which forms part of SARS-CoV-2-human interactome. The high confidence druggable host proteins are also up-regulated during SARS-CoV-2 infection. Mutations occurring in potential hot-spot regions within likely T-cell and B-cell epitopes or in proteins as part of host-viral interactome, could hamper vaccine or drug efficacy in local population. Overall, our study provides comprehensive view of emerging geo-clonal mutations which would aid researchers to understand and develop effective countermeasures in the current crisis.

SignificanceOur comparative analysis of globally dominant mutations and region-specific mutations in 25k SARS-CoV-2 genomes elucidates its geo-clonal evolution. We observe locally dominant mutations (co-occurring or mutually exclusive) in nations with contrasting COVID-19 mortalities per million of population) besides globally dominant ones namely, P314L (ORF1b) and D164G (S) type. We also see exclusive dominant mutations such as in Brazil (I33T in ORF6 and I292T in N protein), England (G251V in ORF3a), India (T2016K and L3606F in ORF1a) and in Spain (L84S in ORF8). The emergence of these local mutations in ORFs within SARS-CoV-2 genome could have interventional implications and also points towards their potential in modulating infectivity of SARS-CoV-2 in regional population.","Rahman, S. A.; Singh, J.; Singh, H.; Hasnain, S. E.","https://www.biorxiv.org/content/10.1101/2020.09.17.301614v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.301614v1?rss=1,2020-09-17,2020-09-17,,False
62,Fixed single-cell RNA sequencing for understanding virus infection and host response,"Single-cell RNA sequencing studies requiring intracellular protein staining, rare-cell sorting, or pathogen inactivation are severely limited because current high-throughput methods are incompatible with paraformaldehyde treatment, a very common and simple tissue/cell fixation and preservation technique. Here we present FD-seq, a high-throughput method for droplet-based RNA sequencing of paraformaldehyde-fixed, stained and sorted single-cells. We used FD-seq to address two important questions in virology. First, by analyzing a rare population of cells supporting lytic reactivation of the human tumor virus KSHV, we identified TMEM119 as a host factor that mediates reactivation. Second, we studied the transcriptome of lung cells infected with the coronavirus OC43, which causes the common cold and also serves as a safer model pathogen for SARS-CoV-2. We found that pro-inflammatory pathways are primarily upregulated in abortively-infected or uninfected bystander cells, which are exposed to the virus but fail to express high level of viral genes. FD-seq is suitable for characterizing rare cell populations of interest, for studying high-containment biological samples after inactivation, and for integrating intracellular phenotypic with transcriptomic information.","Phan, H. V.; van Gent, M.; Drayman, N.; Basu, A.; Gack, M.; Tay, S.","https://www.biorxiv.org/content/10.1101/2020.09.17.302232v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.302232v1?rss=1,2020-09-17,2020-09-17,,False
63,Discovery of human ACE2 variants with altered recognition by the SARS-CoV-2 spike protein,"Understanding how human ACE2 genetic variants differ in their recognition by SARS-CoV-2 can have a major impact in leveraging ACE2 as an axis for treating and preventing COVID-19. In this work, we experimentally interrogate thousands of ACE2 mutants to identify over one hundred human single-nucleotide variants (SNVs) that are likely to have altered recognition by the virus, and make the complementary discovery that ACE2 residues distant from the spike interface can have a strong influence upon the ACE2-spike interaction. These findings illuminate new links between ACE2 sequence and spike recognition, and will find wide-ranging utility in SARS-CoV-2 fundamental research, epidemiological analyses, and clinical trial design.","Heinzelman, P.; Romero, P. A.","https://www.biorxiv.org/content/10.1101/2020.09.17.301861v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.301861v1?rss=1,2020-09-17,2020-09-17,,False
64,Structural and Functional Comparison of SARS-CoV-2-Spike Receptor Binding Domain Produced in Pichia pastoris and Mammalian Cells,"The yeast Pichia pastoris is a cost-effective and easily scalable system for recombinant protein production. In this work we compared the conformation of the receptor binding domain (RBD) from SARS-CoV-2 Spike protein expressed in P. pastoris and in the well established HEK-293T mammalian cell system. RBD obtained from both yeast and mammalian cells was properly folded, as indicated by UV-absorption, circular dichroism and tryptophan fluorescence. They also had similar stability, as indicated by temperature-induced unfolding (observed Tm were 50 {degrees}C and 52 {degrees}C for RBD produced in P. pastoris and HEK-293T cells, respectively). Moreover, the stability of both variants was similarly reduced when the ionic strength was increased, in agreement with a computational analysis predicting that a set of ionic interactions may stabilize RBD structure. Further characterization by HPLC, size-exclusion chromatography and mass spectrometry revealed a higher heterogeneity of RBD expressed in P. pastoris relative to that produced in HEK-293T cells, which disappeared after enzymatic removal of glycans. The production of RBD in P. pastoris was scaled-up in a bioreactor, with yields above 45 mg/L of 90% pure protein, thus potentially allowing large scale immunizations to produce neutralizing antibodies, as well as the large scale production of serological tests for SARS-CoV-2.","Argentinian AntiCovid Consortium,; Arbeitman, C. R.; Auge, G.; Blaustein, M.; Bredeston, L.; Corapi, E. S.; Craig, P. O.; Cossio, L. A.; Dain, L.; D'Alessio, C.; Elias, F.; Fernandez, N. B.; Gasulla, J.; Gorojovsky, N.; Gudesblat, G. E.; Herrera, M. G.; Ibanez, L. I.; Idrovo, T.; Iglesias Rando, M.; Kamenetzky, L.; Nadra, A. D.; Noseda, D. G.; Pavan, C. H.; Pavan, M. F.; Pignataro, M. F.; Roman, E.; Ruberto, L. A. M.; Rubinstein, N.; Santos, J.; Velazquez, F.; Zelada, A. M.","https://www.biorxiv.org/content/10.1101/2020.09.17.300335v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.300335v1?rss=1,2020-09-17,2020-09-17,,False
65,"Topography, spike dynamics and nanomechanics of individual native SARS-CoV-2 virions","SARS-CoV-2, the virus responsible for the current COVID-19 pandemic, displays a corona-shaped layer of spikes which play fundamental role in the infection process. Recent structural data suggest that the spikes possess orientational freedom and the ribonucleoproteins segregate into basketlike structures. How these structural features regulate the dynamic and mechanical behavior of the native virion, however, remain unknown. By imaging and mechanically manipulating individual, native SARS-CoV-2 virions with atomic force microscopy, here we show that their surface displays a dynamic brush owing to the flexibility and rapid motion of the spikes. The virions are highly compliant and able to recover from drastic mechanical perturbations. Their global structure is remarkably temperature resistant, but the virion surface becomes progressively denuded of spikes upon thermal exposure. Thus, both the infectivity and thermal sensitivity of SARS-CoV-2 rely on the dynamics and the mechanics of the virus.

One sentence summaryThe native coronavirus 2 displays a dynamic surface layer of spikes, a large mechanical compliance and unique self-healing capacity.","Kiss, B.; Kis, Z.; Palyi, B.; Kellermayer, M.","https://www.biorxiv.org/content/10.1101/2020.09.17.302380v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.17.302380v1?rss=1,2020-09-17,2020-09-17,,False
66,Mouse model for testing SARS-CoV-2 antivirals: Pharmacokinetics,"Background and ObjectivesRemdesivir and hydroxychloroquine are or were among the most promising therapeutic options to tackle the current SARS-CoV-2 pandemic. Besides the use of the prodrug remdesivir itself, the direct administration of GS-441 524, the resulting main metabolite of remdesivir, could be advantageous and even more effective. All substances were not originally developed for the treatment of COVID-19 and especially for GS-441 524 little is known about its pharmacokinetic and physical-chemical properties. To justify the application of new or repurposed drugs in humans, pre-clinical in vivo animal models are mandatory to investigate relevant PK and PD properties and their relationship to each other. In this study, an adapted mouse model was chosen to demonstrate its suitability to provide sufficient information on the model substances GS-441 524 and HCQ regarding plasma concentration and distribution into relevant tissues a prerequisite for treatment effectiveness.

MethodsGS-441 524 and HCQ were administered intravenously as a single injection to male mice. Blood and organ samples were taken at several time points and drug concentrations were quantified in plasma and tissue homogenates by two liquid chromatography/tandem mass spectrometry methods. In vitro experiments were conducted to investigate the degradation of remdesivir in human plasma and blood. All pharmacokinetic analyses were performed with R Studio using non-compartmental analysis.

ResultsHigh tissue to plasma ratios for GS-441 524 and HCQ were found, indicating a significant distribution into the examined tissue, except for the central nervous system and fat. For GS-441 524, measured tissue concentrations exceeded the reported in vitro EC50 values by more than 10-fold and in consideration of its high efficacy against feline infectious peritonitis, GS-441 524 could indeed be effective against SARS-CoV-2 in vivo. For HCQ, relatively high in vitro EC50 values are reported, which were not reached in all tissues. Facing its slow tissue distribution, HCQ might not lead to sufficient tissue saturation for a reliable antiviral effect.

ConclusionThe mouse model was able to characterise the PK and tissue distribution of both model substances and is a suitable tool to investigate early drug candidates against SARS-CoV-2. Furthermore, we could demonstrate a high tissue distribution of GS-441 524 even if not administered as the prodrug remdesivir.","Scherf-Clavel, O.; Kinzig, M.; Friedl, B.; Kaczmarek, E.; Feja, M.; Gernert, M.; Richter, F.; Hoehl, R.; Nau, R.; Holzgrabe, U.; Soergel, F.","https://www.biorxiv.org/content/10.1101/2020.09.16.299537v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.299537v1?rss=1,2020-09-16,2020-09-16,,False
67,Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing,"SARS-CoV-2 is the causative agent behind the COVID-19 pandemic, and responsible for tens of millions of infections, and hundreds of thousands of deaths worldwide. Efforts to test, treat and vaccinate against this pathogen all benefit from an improved understanding of the basic biology of SARS-CoV-2. Both viral and cellular proteases play a crucial role in SARS-CoV-2 replication, and inhibitors targeting proteases have already shown success at inhibiting SARS-CoV-2 in cell culture models. Here, we study proteolytic cleavage of viral and cellular proteins in two cell line models of SARS-CoV-2 replication using mass spectrometry to identify protein neo-N-termini generated through protease activity. We identify multiple previously unknown cleavage sites in multiple viral proteins, including major antigenic proteins S and N, which are the main targets for vaccine and antibody testing efforts. We discovered significant increases in cellular cleavage events consistent with cleavage by SARS-CoV-2 main protease, and identify 14 potential high-confidence substrates of the main and papain-like proteases. We showed that siRNA depletion of these cellular proteins inhibits SARS-CoV-2 replication, and that drugs targeting two of these proteins: the tyrosine kinase SRC and Ser/Thr kinase MYLK, showed a dose-dependent reduction in SARS-CoV-2 titres. Overall, our study provides a powerful resource to understand proteolysis in the context of viral infection, and to inform the development of targeted strategies to inhibit SARS-CoV-2 and treat COVID-19 disease.","Meyer, B.; Chiaravalli, J.; Brownridge, P.; Bryne, D. P.; Daly, L. A.; Agou, F.; Eyers, C. E.; Eyers, P. A.; Vignuzzi, M.; Emmott, E.","https://www.biorxiv.org/content/10.1101/2020.09.16.297945v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.297945v1?rss=1,2020-09-16,2020-09-16,,False
68,The flexibility of ACE2 in the context of SARS-CoV-2 infection,"The COVID-19 pandemic has swept over the world in the past months, causing significant loss of life and consequences to human health. Although numerous drug and vaccine developments efforts are underway, many questions remain outstanding on the mechanism of SARS-CoV-2 viral association to angiotensin-converting enzyme 2 (ACE2), its main host receptor, and entry in the cell. Structural and biophysical studies indicate some degree of flexibility in the viral extracellular Spike glycoprotein and at the receptor binding domain-receptor interface, suggesting a role in infection. Here, we perform all-atom molecular dynamics simulations of the glycosylated, full-length membrane-bound ACE2 receptor, in both an apo and spike receptor binding domain (RBD) bound state, in order to probe the intrinsic dynamics of the ACE2 receptor in the context of the cell surface. A large degree of fluctuation in the full length structure is observed, indicating hinge bending motions at the linker region connecting the head to the transmembrane helix, while still not disrupting the ACE2 homodimer or ACE2-RBD interfaces. This flexibility translates into an ensemble of ACE2 homodimer conformations that could sterically accommodate binding of the spike trimer to more than one ACE2 homodimer, and suggests a mechanical contribution of the host receptor towards the large spike conformational changes required for cell fusion. This work presents further structural and functional insights into the role of ACE2 in viral infection that can be exploited for the rational design of effective SARS-CoV-2 therapeutics.

Statement of SignificanceAs the host receptor of SARS-CoV-2, ACE2 has been the subject of extensive structural and antibody design efforts in aims to curtail COVID-19 spread. Here, we perform molecular dynamics simulations of the homodimer ACE2 full-length structure to study the dynamics of this protein in the context of the cellular membrane. The simulations evidence exceptional plasticity in the protein structure due to flexible hinge motions in the head-transmembrane domain linker region and helix mobility in the membrane, resulting in a varied ensemble of conformations distinct from the experimental structures. Our findings suggest a dynamical contribution of ACE2 to the spike glycoprotein shedding required for infection, and contribute to the question of stoichiometry of the Spike-ACE2 complex.","Barros, E. P.; Casalino, L.; Gaieb, Z.; Dommer, A. C.; Wang, Y.; Fallon, L.; Raguette, L.; Belfon, K.; Simmerling, C. L.; Amaro, R. E.","https://www.biorxiv.org/content/10.1101/2020.09.16.300459v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300459v1?rss=1,2020-09-16,2020-09-16,,False
69,SARS-CoV-2 protein Nsp1 alters actomyosin cytoskeleton and phenocopies arrhythmogenic cardiomyopathy-related PKP2 mutant,"Mutations in desmosomal Plakophilin-2 (PKP2) are the most prevalent drivers of arrhythmogenic cardiomyopathy (ACM) and a common cause of sudden cardiac death in young athletes. However, partner proteins that elucidate PKP2 cellular mechanism to understand cardiac dysfunction in ACM are mostly unknown. Here we identify the actin-based motor proteins Myh9 and Myh10 as key PKP2 interactors, and demonstrate that the expression of the ACM-related PKP2 mutant R735X alters actin fiber organization and cell mechanical stiffness. We also show that SARS-CoV-2 Nsp1 protein acts similarly to this known pathogenic R735X mutant, altering the actomyosin component distribution on cardiac cells. Our data reveal that the viral Nsp1 hijacks PKP2 into the cytoplasm and mimics the effect of delocalized R735X mutant. These results demonstrate that cytoplasmic PKP2, wildtype or mutant, induces the collapse of the actomyosin network, since shRNA-PKP2 knockdown maintains the cell structure, validating a critical role of PKP2 localization in the regulation of actomyosin architecture. The fact that Nsp1 and PKP2 mutant R735X share similar phenotypes also suggests that direct SARS-CoV-2 heart infection could induce a transient ACM-like disease in COVID-19 patients, which may contribute to right ventricle dysfunction, observed in patients with poor survival prognosis.

HighlightsThe specific cardiac isoform Plakophilin-2a (PKP2) interacts with Myh9 and Myh10.

PKP2 delocalization alters actomyosin cytoskeleton component organization. SARS-CoV-2 Nsp1 protein hijacks PKP2 from the desmosome into the soluble fraction where it is downregulated.

Viral Nsp1 collapses the actomyosin cytoskeleton and phenocopies the arrhythmogenic cardiomyopathy-related mutant R735X.","Marquez-Lopez, C.; Roche-Molina, M.; Garcia-Quintans, N.; Sacristan, S.; Siniscalco, D.; Gonzalez-Guerra, A.; Camafeita, E.; Lytvyn, M.; Guillen, M. I.; Sanz-Rosa, D.; Martin-Perez, D.; Sanchez-Ramos, C.; Garcia, R.; Bernal, J. A.","https://www.biorxiv.org/content/10.1101/2020.09.14.296178v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296178v1?rss=1,2020-09-16,2020-09-16,,False
70,Efficient production of Moloney murine leukemia virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak that started in China at the end of 2019 has rapidly spread to become pandemic. Several investigational vaccines that have already been tested in animals and humans were able to induce neutralizing antibodies against the SARS-CoV-2 spike (S) protein, however protection and long-term efficacy in humans remain to be demonstrated.

We have investigated if a virus-like particle (VLP) derived from Moloney murine leukemia virus (MLV) could be engineered to become a candidate SARS-CoV-2 vaccine amenable to mass production. First, we showed that a codon optimized version of the S protein could migrate efficiently to the cell membrane. However, efficient production of infectious viral particles was only achieved with stable expression of a shorter version of S in its C-terminal domain ({Delta}S) in 293 cells that express MLV Gag-Pol (293GP). The incorporation of {Delta}S was 15-times more efficient into VLPs as compared to the full-length version, and that was not due to steric interference between the S cytoplasmic tail and the MLV capsid. Indeed, a similar result was also observed with extracellular vesicles released from parental 293 and 293GP cells. The amount of {Delta}S incorporated into VLPs released from producer cells was robust, with an estimated 1.25 g/ml S2 equivalent (S is comprised of S1 and S2). Thus, a scalable platform that has the potential for production of pan-coronavirus VLP vaccines has been established. The resulting nanoparticles could potentially be used alone or as a boost for other immunization strategies for COVID-19.

IMPORTANCESeveral candidate COVID-19 vaccines have already been tested in humans, but their protective effect and long-term efficacy are uncertain. Therefore, it is necessary to continue developing new vaccine strategies that could be more potent and/or that would be easier to manufacture in large-scale. Virus-like particle (VLP) vaccines are considered highly immunogenic and have been successfully developed for human papilloma virus as well as hepatitis and influenza viruses. In this study, we report the generation of a robust Moloney murine leukemia virus platform that produces VLPs containing the spike of SARS-CoV-2. This vaccine platform that is compatible with lyophilization could simplify storage and distribution logistics immensely.","Caruso, M.; Roy, S.; Ghani, K.; de Campos-Lima, P. O.","https://www.biorxiv.org/content/10.1101/2020.09.16.298992v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.298992v1?rss=1,2020-09-16,2020-09-16,,False
71,High affinity modified ACE2 receptors prevent SARS-CoV-2 infection,"The SARS-CoV-2 spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor via receptor binding domain (RBD) to enter into the cell. Inhibiting this interaction is a main approach to block SARS-CoV-2 infection and it is required to have high affinity to RBD independently of viral mutation for effective protection. To this end, we engineered ACE2 to enhance the affinity with directed evolution in human cells. Three cycles of random mutation and cell sorting achieved more than 100-fold higher affinity to RBD than wild-type ACE2. The extracellular domain of modified ACE2 fused to the Fc region of the human immunoglobulin IgG1 had stable structure and neutralized SARS-CoV-2 pseudotyped lentivirus and authentic virus with more than 100-fold lower concentration than wild-type. Engineering ACE2 decoy receptors with directed evolution is a promising approach to develop a SARS-CoV-2 neutralizing drug that has affinity comparable to monoclonal antibodies yet displaying resistance to escape mutations of virus.","Higuchi, Y.; Suzuki, T.; Arimori, T.; Ikemura, N.; Kirita, Y.; Ohgitani, E.; Mazda, O.; Motooka, D.; Nakamura, S.; Matsuura, Y.; Matoba, S.; Okamoto, T.; Takagi, J.; Hoshino, A.","https://www.biorxiv.org/content/10.1101/2020.09.16.299891v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.299891v1?rss=1,2020-09-16,2020-09-16,,False
72,Structure Model Analysis Of Phosphorylation Dependent Binding And Sequestration Of SARS-COV-2 Encoded Nucleocapsid Protein By Protein 14-3-3,"Phosphorylation of serines 197 and 206 of SARS-COV-2 Nucleocapsid protein (NCp) enhanced the stability and binding efficiency and sequestration of NCp to Protein 14-3-3 by increasing the Stability Energy ({Delta}Gstability energy) and Binding Energy ({Delta}{Delta}Gbinding energy) from ~545 Kcal/mol to ~616 Kcal/mol, and from 108 Kcal/mol to ~228 Kcal/mol respectively. The calculated Binding Energy Difference ({Delta}{Delta}Gbinding energy difference) between dephospho-NCp-14-3-3 complex and phospho-NCp-13-3-3 complex was ~72 Kcal/mol. Phosphorylations of serines 186, 197, 202 and 206, and threonines 198 and 205 NCp also caused an increase in the Stability Energy ({Delta}Gstability energy) and Binding Energy ({Delta}{Delta}Gbinding energy) from ~545 Kcal/mol to ~617, 616, 583, 580, 574, 564 and 566 Kcal/mol and from ~108 Kcal/mol to ~228, 216, 184, 188, 184, 174 and 112 Kcal/mol respectively. Phosphorylation of NCp on serines 197 and 206 caused a decrease in Stability Energy and Binding Energy from ~698 Kcal/mol to 688 Kcal/mol, and from ~91 Kcal/mol to ~82 Kcal/mol for the dimerization of NCp. These results support the existence of a phosphorylation dependent cellular mechanism to bind and sequester NCp.","Tung, H. Y. L.; Limtung, P.","https://www.biorxiv.org/content/10.1101/2020.09.16.299362v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.299362v1?rss=1,2020-09-16,2020-09-16,,False
73,"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors","There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the viral main protease (Mpro) is one of the most extensively studied drug targets. Mpro is a cysteine protease that hydrolyzes the viral polyprotein at more than 11 sites and it is highly conserved among coronaviruses. In addition, Mpro has a unique substrate preference for glutamine in the P1 position. Taken together, it appears that Mpro inhibitors can achieve both broad-spectrum antiviral activity and a high selectivity index. Structurally diverse compounds have been reported as Mpro inhibitors, with several of which also showed antiviral activity in cell culture. In this study, we investigated the mechanism of action of six previously reported Mpro inhibitors, ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12 using a consortium of techniques including FRET-based enzymatic assay, thermal shift assay, native mass spectrometry, cellular antiviral assays, and molecular dynamics simulations. Collectively, the results showed that the inhibition of Mpro by these six compounds is non-specific and the inhibition is abolished or greatly reduced with the addition of reducing reagent DTT. In the absence of DTT, these six compounds not only inhibit Mpro, but also a panel of viral cysteine proteases including SARS-CoV-2 papain-like protease, the 2Apro and 3Cpro from enterovirus A71 (EV-A71) and EV-D68. However, none of the compounds inhibits the viral replication of EV-A71 or EV-D68, suggesting that the enzymatic inhibition potency IC50 values obtained in the absence of DTT cannot be used to faithfully predict their cellular antiviral activity. Overall, we provide compelling evidence suggesting that ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12 are non-specific SARS-CoV-2 Mpro inhibitors, and urge the scientific community to be stringent with hit validation.

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=92 SRC=""FIGDIR/small/299164v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (13K):
org.highwire.dtl.DTLVardef@321f6forg.highwire.dtl.DTLVardef@adc714org.highwire.dtl.DTLVardef@e8f993org.highwire.dtl.DTLVardef@1593c01_HPS_FORMAT_FIGEXP  M_FIG C_FIG","Ma, C.; Hu, Y.; Townsend, J. A.; Lagarias, P.; Marty, M. T.; Kolocouris, A.; Wang, J.","https://www.biorxiv.org/content/10.1101/2020.09.15.299164v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.299164v1?rss=1,2020-09-16,2020-09-16,,False
74,Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function,"BackgroundThe emergence of a novel coronavirus (SARS-CoV-2) associated with severe acute respiratory disease (COVID-19) has prompted efforts to understand the genetic basis for its unique characteristics and its jump from non-primate hosts to humans. Tests for positive selection can identify apparently nonrandom patterns of mutation accumulation within genomes, highlighting regions where molecular function may have changed during the origin of a species. Several recent studies of the SARS-CoV-2 genome have identified signals of conservation and positive selection within the gene encoding Spike protein based on the ratio of synonymous to nonsynonymous substitution. Such tests cannot, however, detect changes in the function of RNA molecules.

MethodsHere we apply a test for branch-specific oversubstitution of mutations within narrow windows of the genome without reference to the genetic code.

ResultsWe recapitulate the finding that the gene encoding Spike protein has been a target of both purifying and positive selection. In addition, we find other likely targets of positive selection within the genome of SARS-CoV-2, specifically within the genes encoding Nsp4 and Nsp16. Homology-directed modeling indicates no change in either Nsp4 or Nsp16 protein structure relative to the most recent common ancestor. Thermodynamic modeling of RNA stability and structure, however, indicates that RNA secondary structure within both genes in the SARS-CoV-2 genome differs from those of RaTG13, the reconstructed common ancestor, and Pan-CoV-GD (Guangdong). These SARS-CoV-2-specific mutations may affect molecular processes mediated by the positive or negative RNA molecules, including transcription, translation, RNA stability, and evasion of the host innate immune system. Our results highlight the importance of considering mutations in viral genomes not only from the perspective of their impact on protein structure, but also how they may impact other molecular processes critical to the viral life cycle.","Berrio, A.; Gartner, V.; Wray, G. A.","https://www.biorxiv.org/content/10.1101/2020.09.16.300038v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300038v1?rss=1,2020-09-16,2020-09-16,,False
75,Evaluation of nafamostat mesylate safety and inhibition of SARS-CoV-2 replication using a 3-dimensional human airway epithelia model,"In the current COVID-19 pandemic context, Ensysce and its subsidiary Covistat have been working to repurpose nafamostat mesylate as an effective oral and inhalation treatment against SARS-CoV-2 infection. Prior reports used cell lines to demonstrate the antiviral potential of nafamostat against coronaviral infections and determined its mechanism of action through inhibition of transmembrane protease serine 2 (TMPRSS2). We selected a biologically relevant pre-clinical experimental model of SARS-CoV-2 lung infection using a 3D human reconstituted airway epithelial model of nasal origin to characterize the effects of nafamostat on tissue-level cellular ultrastructure and viral infection kinetics. Our results confirm the not only the relevance of this model for the preclinical evaluation of safety and efficacy of antiviral candidates, but also the highly potent nature of nafamostat SARS-CoV-2 antiviral activity. The studies described herein provided evidence demonstrating the therapeutic potential of nafamostat against COVID-19, as well as its safety upon exposure to lung airway cellular.

One Sentence SummaryUsing a human airway model, study demonstrates the powerful inhibitory effect of nafamostat on SARS-CoV-2 genome copy detection when applied apically.","Kirkpatrick, L.; Millard, J.","https://www.biorxiv.org/content/10.1101/2020.09.16.300483v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300483v1?rss=1,2020-09-16,2020-09-16,,False
76,Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro,"COVID-19 has caused over 900,000 deaths worldwide as of September 2020, and effective medicines are urgently needed. Lopinavir was identified as an inhibitor of the HIV protease, and a lopinavir-ritonavir combination therapy was reported to be beneficial for the treatment of SARS and MERS. However, recent clinical tests could not prove that lopinavir-ritonavir therapy was an effective treatment for COVID-19. In this report, we examined the effect of lopinavir and ritonavir to the activity of the purified main protease (Mpro) protein of SARS- CoV-2, the causative virus of COVID-19. Unexpectedly, lopinavir and ritonavir did not inhibit Mpro activity. These results will aid the drug candidate selection for ongoing and future COVID-19 clinical trials.","Jang, M.; Park, Y.-I.; Park, R.; Cha, Y.-E.; Namkoong, S.; Lee, J. I.; Park, J.","https://www.biorxiv.org/content/10.1101/2020.09.16.299800v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.299800v1?rss=1,2020-09-16,2020-09-16,,False
77,Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells,"Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The initial interaction between Transmembrane Serine Protease 2 (TMPRSS2) primed SARS-CoV-2 spike (S) protein and host cell receptor angiotensin-converting enzyme 2 (ACE-2) is a pre-requisite step for this novel coronavirus pathogenesis. Here, we expressed a GFP-tagged SARS-CoV-2 S-Ectodomain in Tni insect cells. That contained sialic acid-enriched N- and O-glycans. Surface resonance plasmon (SPR) and Luminex assay showed that the purified S-Ectodomain binding to human ACE-2 and immunoreactivity with COVID-19 positive samples. We demonstrate that bromelain (isolated from pineapple stem and used as a dietary supplement) treatment diminishes the expression of ACE-2 and TMPRSS2 in VeroE6 cells and dramatically lowers the expression of S-Ectodomain. Importantly, bromelain treatment reduced the interaction between S-Ectodomain and VeroE6 cells. Most importantly, bromelain treatment significantly diminished the SARS-CoV-2 infection in VeroE6 cells. Altogether, our results suggest that bromelain or bromelain rich pineapple stem may be used as an antiviral against COVID-19.

Highlights

O_FIG O_LINKSMALLFIG WIDTH=178 HEIGHT=200 SRC=""FIGDIR/small/297366v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (35K):
org.highwire.dtl.DTLVardef@b7afb0org.highwire.dtl.DTLVardef@16f8185org.highwire.dtl.DTLVardef@1a07df8org.highwire.dtl.DTLVardef@1ae33fa_HPS_FORMAT_FIGEXP  M_FIG C_FIG O_LIBromelain inhibits / cleaves the expression of ACE-2 and TMPRSS2
C_LIO_LIBromelain cleaves / degrades SARS-CoV-2 spike protein
C_LIO_LIBromelain inhibits S-Ectodomain binding and SARS-CoV-2 infection
C_LI","Sagar, S.; Rathinavel, A. K.; Lutz, W. E.; Struble, L. R.; Khurana, S.; Schnaubelt, A. T.; Mishra, N. K.; Guda, C.; Broadhurst, M. J.; Reid, S. P.; Bayles, K. W.; Borgstahl, G. E. O.; Radhakrishnan, P.","https://www.biorxiv.org/content/10.1101/2020.09.16.297366v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.297366v1?rss=1,2020-09-16,2020-09-16,,False
78,Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques,"Effective therapeutics aimed at mitigating COVID-19 symptoms are urgently needed. SARS-CoV-2 induced hypercytokinemia and systemic inflammation are associated with disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor with potent anti-inflammatory properties is currently being investigated in COVID-19 human clinical trials. Recent reports suggest that baricitinib may also have antiviral activity in limiting viral endocytosis. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type I IFN antiviral responses and SARS-CoV-2 specific T cell responses remained similar between the two groups. Importantly, however, animals treated with baricitinib showed reduced immune activation, decreased infiltration of neutrophils into the lung, reduced NETosis activity, and more limited lung pathology. Moreover, baricitinib treated animals had a rapid and remarkably potent suppression of alveolar macrophage derived production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for severe inflammation induced by SARS-CoV-2 infection.","Hoang, T. N.; Pino, M.; Boddapati, A. K.; Viox, E. G.; Starke, C. E.; Upadhyay, A. A.; Gumber, S.; Busman-Sahay, K.; Strongin, Z.; Harper, J. L.; Tharp, G. K.; Pellegrini, K. L.; Kirejczyk, S.; Zandi, K.; Tao, S.; Horton, T. R.; Beagle, E. N.; Mahar, E. A.; Lee, M. Y.; Cohen, J.; Jean, S.; Wood, J. S.; Connor-Stroud, F.; Stammen, R. L.; Delmas, O. M.; Wang, S.; Cooney, K. A.; Sayegh, M. N.; Wang, L.; Weiskopf, D.; Filev, P. D.; Waggoner, J.; Piantadosi, A.; Kasturi, S. P.; Al-Shakhshir, H.; Ribeiro, S. P.; Sekaly, R. P.; Levit, R. D.; Estes, J. D.; Vanderford, T. H.; Schinazi, R. F.; Bosinger, S. E.; Paiardini, M.","https://www.biorxiv.org/content/10.1101/2020.09.16.300277v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.16.300277v1?rss=1,2020-09-16,2020-09-16,,False
79,"The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro","BackgroundThe COVID-19 pandemic is an enormous threat for healthcare systems and economies worldwide that urgently demands effective preventive and therapeutic strategies. Unlike the development of vaccines and new drugs specifically targeting SARS-CoV-2, repurposing of approved or clinically tested drugs can provide an immediate solution.

MethodsWe applied a novel computational approach to search among approved and clinically tested drugs from the DrugBank database. Candidates were selected based on Shannon entropy homology and predefined activity profiles of three small molecules with proven anti-SARS-CoV activity and a published data set. Antiviral activity of a predicted drug, azelastine, was tested in vitro in SARS-CoV-2 infection assays with Vero E6 monkey kidney epithelial cells and reconstituted human nasal tissue. The effect on viral replication was assessed by quantification of viral genomes by droplet digital PCR.

FindingsThe computational approach with four independent queries identified major drug families, most often and in overlapping fashion anti-infective, anti-inflammatory, anti-hypertensive, anti-histamine and neuroactive drugs. Azelastine, an histamine 1 receptor-blocker, was predicted in multiple screens, and based on its attractive safety profile and availability in nasal formulation, was selected for experimental testing. Azelastine significantly reduced cytopathic effect and SARS-CoV-2 infection of Vero E6 cells with an EC50 of [~]6 M both in a preventive and treatment setting. Furthermore, azelastine in a commercially available nasal spray tested at 5-fold dilution was highly potent in inhibiting viral propagation in SARS-CoV-2 infected reconstituted human nasal tissue.

InterpretationsAzelastine, an anti-histamine, available in nasal sprays developed against allergic rhinitis may be considered as a topical prevention or treatment of nasal colonization with SARS-CoV-2. As such, it could be useful in reducing viral spread and prophylaxis of COVID-19. Ultimately, its potential benefit should be proven in clinical studies.

Fundingprovided by the Hungarian government to the National Laboratory of Virology and by CEBINA GmbH.","Konrat, R.; Papp, H.; Szijarto, V.; Gesell, T.; Nagy, G.; Madai, M.; Zeghbib, S.; Kuczmog, A.; Lanszki, Z.; Helyes, Z.; Kemenesi, G.; Jakab, F.; Nagy, E.","https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1?rss=1,2020-09-15,2020-09-15,,False
80,"Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo","SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination in vivo. Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA. The data indicate that hu-mAb protective activity is dependent on intact effector function and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.","Schaefer, A.; Muecksch, F.; Lorenzi, J. C. C.; Leist, S. R.; Cipolla, M.; Bournazos, S.; Schmidt, F.; Gazumyan, A.; Baric, R. S.; Robbiani, D. F.; Hatziioannou, T.; Ravetch, J. V.; Bieniasz, P. D.; Nussenzweig, M. C.; Sheahan, T. P.","https://www.biorxiv.org/content/10.1101/2020.09.15.298067v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.298067v1?rss=1,2020-09-15,2020-09-15,,False
81,Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction,"Coronavirus Disease 2019 (COVID-19) spreads globally as a sever pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Cell entry of SARS-CoV-2 mainly depends on binding of the viral spike (S) proteins to angiotensin converting enzyme 2 (ACE2) on host cells. Therefore, repurposing of known drugs to inhibit S protein-ACE2 interaction could be a quick way to develop effective therapy for COVID-19. Using a high-throughput screening system to investigate the interaction between spike receptor binding domain (S-RBD) and ACE2 extracellular domain, we screened 3581 FDA-approved drugs and natural small molecules and identified ceftazidime as a potent compound to inhibit S-RBD-ACE2 interaction by binding to S-RBD. In addition to significantly inhibit S-RBD binding to HPAEpiC cells, ceftazidime efficiently prevented SARS-CoV-2 pseudovirus to infect ACE2-expressing 293T cells. The inhibitory concentration (IC50) was 113.2 M, which is far below the blood concentration (over 300 M) of ceftazidime in patients when clinically treated with recommended dose. Notably, ceftazidime is a drug clinically used for the treatment of pneumonia with minimal side effects compared with other antiviral drugs. Thus, ceftazidime has both anti-bacterial and anti-SARS-CoV-2 effects, which should be the first-line antibiotics used for the clinical treatment of COVID-19.","Lin, C.; Li, Y.; Yuan, M.; Huang, M.; Liu, C.; Du, H.; Pan, X.; Wen, Y.; Xu, X.; Xu, C.; Chen, J.","https://www.biorxiv.org/content/10.1101/2020.09.14.295956v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.295956v1?rss=1,2020-09-15,2020-09-15,,False
82,Emergence and expansion of highly infectious spike:D614G mutant SARS-CoV-2 in central India,"COVID 19 has emerged as global pandemic with largest damage to the economy and human psyche. The genomic signature deciphered during the ongoing pandemic period is valuable to understand the virus evolutionary patterns and spread across the globe. Increased availability of genome information of circulating strain in our country will enable to generate selective details in virulent and non virulent markers to prophylaxis and therapeutic interventions. The first case of SARS CoV-2 was detected in Chambal region of Madhya Pradesh state in mid of March 2020 followed by multiple introduction events and expansion of COVID-19 cases within 3 months in this region. We analyzed around 5000 COVID -19 suspected samples referred to Defence Research and Development Establishment, Gwalior, Madhya Pradesh. A total of 136 cases were found positive over a span of three months period this includes virus introduction to region and further spread. Whole genome sequences employing Oxford nanopore technology were deciphered for 26 SARS-CoV-2 circulating in 10 different districts in Madhya Pradesh State of India. The region witnessed index cases with multiple travel history responsible for introduction of COVID-19 followed by remarkable expansion of virus. The genome wide substitutions including in important viral proteins were observed. The detailed phylogenetic analysis revealed the circulating SARS-CoV-2 clustered in multiple clades A2a, A4 and B. The cluster wise segregation was observed suggesting multiple introduction links and evolution of virus in the region. This is the first comprehensive details of whole genome sequence analysis from central India region, which will add genome wide knowledge towards diagnostic and therapeutic interventions.","Sharma, S.; Dash, P. K.; Sharma, S. K.; Srivastava, A.; Kumar, J. S.; Karothia, B. S.; Chelvam, K. T.; Singh, S.; Gupta, A.; Yadav, R. G.; Yadav, R.; S, G. T.; Kushwah, P.; Bhushan, R.; Nagar, D. P.; Nandan, M.; Kumar, S.; Thavaselvam, D.; Dubey, D. K.","https://www.biorxiv.org/content/10.1101/2020.09.15.297846v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.297846v1?rss=1,2020-09-15,2020-09-15,,False
83,Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy,"Adoptive cell therapy with viral-specific T cells has been successfully used to treat life-threatening viral infections, supporting the application of this approach against COVID-19. We expanded SARS-CoV-2 T-cells from the peripheral blood of COVID-19-recovered donors and non-exposed controls using different culture conditions. We observed that the choice of cytokines modulates the expansion, phenotype and hierarchy of antigenic recognition by SARS-CoV-2 T-cells. Culture with IL-2/4/7 but not other cytokine-driven conditions resulted in >1000 fold expansion in SARS-CoV-2 T-cells with a retained phenotype, function and hierarchy of antigenic recognition when compared to baseline (pre-expansion) samples. Expanded CTLs were directed against structural SARS-CoV-2 proteins, including the receptor-binding domain of Spike. SARS-CoV-2 T-cells could not be efficiently expanded from the peripheral blood of non-exposed controls. Since corticosteroids are used for the management of severe COVID-19, we developed an efficient strategy to inactivate the glucocorticoid receptor gene (NR3C1) in SARS-CoV-2 CTLs using CRISPR-Cas9 gene editing.","Basar, R.; Uprety, N.; Ensley, E.; Daher, M.; Klein, K.; Martinez, F.; Aung, F.; Shanley, M.; Hu, B.; Gokdemir, E.; Mendt, M.; Reyes Silva, F.; Acharya, S.; Laskowski, T.; Muniz-Feliciano, L.; Banerjee, P.; Li, Y.; Li, S.; Melo Garcia, L.; Lin, P.; Shaim, H.; Yates, S. G.; Marin, D.; Kaur, I.; Rao, S.; Mak, D.; Lin, A.; Miao, Q.; Dou, J.; Chen, K.; Champlin, R.; Shpall, E. J.; Rezvani, K.","https://www.biorxiv.org/content/10.1101/2020.09.15.298547v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.298547v1?rss=1,2020-09-15,2020-09-15,,False
84,Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases,"The coronavirus main protease, Mpro, is a key protein in the virus life cycle and a major drug target. Based on crystal structures of SARSCoV2 Mpro complexed with peptidomimetic inhibitors, we recognized a binding characteristic shared with proline-containing inhibitors of hepatitis C virus protease. Initial tests showed that this subclass of HCV protease inhibitors indeed exhibited activity against Mpro. Postulating a benefit for a preorganized backbone conformation, we designed new ketoamide-based Mpro inhibitors based on central proline rings. One of the designed compounds, ML1000, inhibits Mpro with low-nanomolar affinity and suppresses SARSCoV2 viral replication in human cells at sub-micromolar concentrations. Our findings identify ML1000 as a promising new pre-organized scaffold for the development of anti-coronavirus drugs.","Westberg, M.; Su, Y.; Zou, X.; Hurst, B.; Tarbet, B.; Lin, M.","https://www.biorxiv.org/content/10.1101/2020.09.15.275891v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.275891v1?rss=1,2020-09-15,2020-09-15,,False
85,Levels of genetic diversity of SARS-CoV-2 virus: reducing speculations about the genetic variability of the virus in South America,"In this work, we evaluated the levels of genetic diversity in 38 complete Genomes of SARS-CoV-2 from six countries in South America, using specific methodologies for paired FST, AMOVA, mismatch, demographic and spatial expansions, molecular diversity and for the time of evolutionary divergence. The analyses showed non-significant evolutionary divergences within and between the six countries, as well as a significant similarity to the time of genetic evolutionary divergence between all populations. Thus, it seems safe to affirm that we will find similar results for the other Countries of South America, reducing speculation about the existence of rapid and silent mutations that, although there are as we have shown in this work, do not increase, until this moment, the genetic variability of the Virus, a fact that would hinder the work with molecular targets for vaccines and drugs in general.","Filho, C. B. d. N.; Ramos, R. d. S.; Paulino, A. J.; Venancio, D. B. R.; Felix, P. T.","https://www.biorxiv.org/content/10.1101/2020.09.14.296491v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296491v1?rss=1,2020-09-15,2020-09-15,,False
86,LOX-1+ immature neutrophils predict severe COVID-19 patients at risk of thrombotic complications,"RationalLymphopenia and neutrophil/lymphocyte ratio may have prognostic value in coronavirus disease 2019 (COVID-19) severity.

ObjectiveWe sought to investigate the representation of neutrophil subsets in severe and critical COVID-19 patients based on Intensive Care Units (ICU) and non-ICU admission.

MethodsWe developed a multi-parametric neutrophil profiling strategy based on known neutrophil markers to distinguish COVID-19 phenotypes in critical and severe patients.

ResultsOur results showed that 80% of ICU patients develop strong myelemia with CD10-CD64+ immature neutrophils. Cellular profiling revealed two distinct neutrophil subsets expressing either the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) or the Interleukin-3 receptor alpha (CD123), both significantly overrepresented in ICU patients compared to non-ICU patients. The proportion of LOX-1-expressing immature neutrophils positively correlated with clinical severity, with the cytokine storm (IL-1{beta}, IL-6, IL-8, TNF), and with intravascular coagulation. Importantly, high proportions of LOX-1+-immature neutrophils are associated with high risks of severe thrombosis.

ConclusionsTogether these data suggest that point of care enumeration of LOX-1-immature neutrophils might help distinguish patients at risk of thrombosis complication and most likely to benefit from intensified anticoagulant therapy.","Combadiere, B.; Adam, L.; Quentric, P.; Rosenbaum, P.; Dorgham, K.; Bonduelle, O.; Parizot, C.; Sauce, D.; Mayaux, J.; Luyt, C.-E.; Boissonnas, A.; Amoura, Z.; Pourcher, V.; Miyara, M.; Gorochov, G.; Guihot, A.; Combadiere, C.","https://www.biorxiv.org/content/10.1101/2020.09.15.293100v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.293100v1?rss=1,2020-09-15,2020-09-15,,False
87,CROssBAR: Comprehensive Resource of Biomedical Relations with Deep Learning Applications and Knowledge Graph Representations,"Systemic analysis of available large-scale biological and biomedical data is critical for developing novel and effective treatment approaches against both complex and infectious diseases. Owing to the fact that different sections of the biomedical data is produced by different organizations/institutions using various types of technologies, the data are scattered across individual computational resources, without any explicit relations/connections to each other, which greatly hinders the comprehensive multi-omics-based analysis of data. We aimed to address this issue by constructing a new biological and biomedical data resource, CROssBAR, a comprehensive system that integrates large-scale biomedical data from various resources and store them in a new NoSQL database, enrich these data with deep-learning-based prediction of relations between numerous biomedical entities, rigorously analyse the enriched data to obtain biologically meaningful modules and display them to users via easy-to-interpret, interactive and heterogenous knowledge graph (KG) representations within an open access, user-friendly and online web-service at https://crossbar.kansil.org. As a use-case study, we constructed CROssBAR COVID-19 KGs (available at: https://crossbar.kansil.org/covid_main.php) that incorporate relevant virus and host genes/proteins, interactions, pathways, phenotypes and other diseases, as well as known and completely new predicted drugs/compounds. Our COVID-19 graphs can be utilized for a systems-level evaluation of relevant virus-host protein interactions, mechanisms, phenotypic implications and potential interventions.","Dogan, T.; Atas, H.; Joshi, V.; Atakan, A.; Rifaioglu, A. S.; Nalbat, E.; Nightingale, A.; Saidi, R.; Volynkin, V.; Zellner, H.; Cetin-Atalay, R.; Martin, M.; Atalay, V.","https://www.biorxiv.org/content/10.1101/2020.09.14.296889v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296889v1?rss=1,2020-09-15,2020-09-15,,False
88,SARS-CoV-2 ribosomal frameshifting pseudoknot: Improved secondary structure prediction and detection of inter-viral structural similarity,"AO_SCPLOWBSTRACTC_SCPLOWSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the COVID-19 pandemic; a pandemic of a scale that has not been seen in the modern era. Despite over 29 million reported cases and over 900, 000 deaths worldwide as of September 2020, herd immunity and widespread vaccination efforts by many experts are expected to be insufficient in addressing this crisis for the foreseeable future. Thus, there is an urgent need for treatments that can lessen the effects of SARS-CoV-2 in patients who become seriously affected. Many viruses including HIV, the common cold, SARS-CoV and SARS-CoV-2 use a unique mechanism known as -1 programmed ribosomal frameshifting (-1 PRF) to successfully replicate and infect cells in the human host. SARS-CoV (the coronavirus responsible for SARS) and SARS-CoV-2 possess a unique RNA structure, a three-stemmed pseudoknot, that stimulates -1 PRF. Recent experiments identified that small molecules can be introduced as antiviral agents to bind with the pseudoknot and disrupt its stimulation of -1 PRF. If successfully developed, small molecule therapy that targets -1 PRF in SARS-CoV-2 is an excellent strategy to improve patients prognoses. Crucial to developing these successful therapies is modeling the structure of the SARS-CoV-2 -1 PRF pseudoknot. Following a structural alignment approach, we identify similarities in the -1 PRF pseudoknots of the novel coronavirus SARS-CoV-2, the original SARS-CoV, as well as a third coronavirus: MERS-CoV, the coronavirus responsible for Middle East Respiratory Syndrome (MERS). In addition, we provide a better understanding of the SARS-CoV-2 -1 PRF pseudoknot by comprehensively investigating the structural landscape using a hierarchical folding approach. Since understanding the impact of mutations is vital to long-term success of treatments that are based on predicted RNA functional structures, we provide insight on SARS-CoV-2 -1 PRF pseudoknot sequence mutations and their effect on the resulting structure and its function.","Trinity, L.; Lansing, L.; Jabbari, H.; Stege, U.","https://www.biorxiv.org/content/10.1101/2020.09.15.298604v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.15.298604v1?rss=1,2020-09-15,2020-09-15,,False
89,The Coronavirus Network Explorer: Mining a large-scale knowledge graph for effects of SARS-CoV-2 on host cell function,"Building on recent work that identified human host proteins that interact with SARS-CoV-2 viral proteins in the context of an affinity-purification mass spectrometry screen, we use a machine learning-based approach to connect the viral proteins to relevant biological functions and diseases in a large-scale knowledge graph derived from the biomedical literature. Our aim is to explore how SARS-CoV-2 could interfere with various host cell functions, and also to identify additional drug targets amongst the host genes that could potentially be modulated against COVID-19. Results are presented in the form of interactive network visualizations, that allow exploration of underlying experimental evidence. A selection of networks is discussed in the context of recent clinical observations.","Kramer, A.; Billaud, J.-N.; Tugendreich, S.; Shiffman, D.; Jones, M.; Green, J.","https://www.biorxiv.org/content/10.1101/2020.09.14.296327v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296327v1?rss=1,2020-09-14,2020-09-14,,False
90,SARS CoV-2 nucleocapsid protein forms condensates with viral genomic RNA,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes COVID-19, a pandemic that seriously threatens global health. SARS CoV-2 propagates by packaging its RNA genome into membrane enclosures in host cells. The packaging of the viral genome into the nascent virion is mediated by the nucleocapsid (N) protein, but the underlying mechanism remains unclear. Here, we show that the N protein forms biomolecular condensates with viral RNA both in vitro and in mammalian cells. While the N protein forms spherical assemblies with unstructured RNA, it forms mesh like-structures with viral RNA strands that contain secondary structure elements. Cross-linking mass spectrometry identified an intrinsically-disordered region that forms interactions between N proteins in condensates, and truncation of this region disrupts phase separation. By screening 1,200 FDA approved drugs in vitro, we identified a kinase inhibitor nilotinib, which affects the morphology of N condensates in vitro and disrupts phase separation of the N protein in vivo. These results indicate that the N protein compartmentalizes viral RNA in infected cells through liquid-liquid phase separation, and this process can be disrupted by a possible drug candidate.","Jack, A.; Ferro, L. S.; Trnka, M. J.; Wehri, E.; Nadgir, A.; Costa, K.; Schaletzky, J.; Yildiz, A.","https://www.biorxiv.org/content/10.1101/2020.09.14.295824v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.295824v1?rss=1,2020-09-14,2020-09-14,,False
91,Genes with 5' terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 NSP1 protein,"Viruses rely on the host translation machinery to synthesize their own proteins. Consequently, they have evolved varied mechanisms to co-opt host translation for their survival. SARS-CoV-2 relies on a non-structural protein, NSP1, for shutting down host translation. Despite this, it is currently unknown how viral proteins and host factors critical for viral replication can escape a global shutdown of host translation. Here, using a novel FACS-based assay called MeTAFlow, we report a dose-dependent reduction in both nascent protein synthesis and mRNA abundance in cells expressing NSP1. We perform RNA-Seq and matched ribosome profiling experiments to identify gene-specific changes both at the mRNA expression and translation level. We discover a functionally-coherent subset of human genes preferentially translated in the context of NSP1 expression. These genes include the translation machinery components, RNA binding proteins, and others important for viral pathogenicity. Importantly, we also uncover potential mechanisms of preferential translation through the presence of shared sites for specific RNA binding proteins and a remarkable enrichment for 5' terminal oligo-pyrimidine tracts. Collectively, the present study suggests fine tuning of host gene expression and translation by NSP1 despite its global repressive effect on host protein synthesis.","Rao, S.; Hoskins, I.; Garcia, D.; Tonn, T.; Ozadam, H.; Sarinay Cenik, E.; Cenik, C.","https://www.biorxiv.org/content/10.1101/2020.09.13.295493v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.13.295493v1?rss=1,2020-09-14,2020-09-14,,False
92,Single-cell RNA Expression of SARS-CoV-2 Cell Entry Factors in Human Endometrium during Preconception,"We investigated potential SARS-CoV-2 tropism in human endometrium by single-cell RNA-sequencing of viral entry-associated genes in healthy women. Percentages of endometrial cells expressing ACE2, TMPRSS2, CTSB, or CTSL were <2%, 12%, 80%, and 80%, respectively, with 0.7% of cells expressing all four genes. Our findings imply low efficiency of SARS-CoV-2 infection in the endometrium before embryo implantation, providing information to assess preconception risk in asymptomatic carriers.","Vilella Mitjana, F.; Wang, W.; Moreno Gimeno, I.; Quake, S.; Simon, C.","https://www.biorxiv.org/content/10.1101/2020.09.14.296806v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296806v1?rss=1,2020-09-14,2020-09-14,,False
93,Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.,"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), enters the host cells through two main pathways, both involving key interactions between viral envelope-anchored spike glycoprotein of the novel coronavirus and the host receptor, angiotensin-converting enzyme 2 (ACE2). To date, SARS-CoV-2 has infected up to 26 million people worldwide; yet, there is no clinically approved drug or vaccine available. Therefore, a rapid and coordinated effort to re-purpose clinically approved drugs that prevent or disrupt these critical entry pathways of SARS-CoV-2 spike glycoprotein interaction with human ACE2, could potentially accelerate the identification and clinical advancement of prophylactic and/or treatment options against COVID-19, thus providing possible countermeasures against viral entry, pathogenesis and survival. Herein, we discovered that Ambroxol hydrochloride (AMB), and its progenitor, Bromhexine hydrochloride (BHH), both clinically approved drugs are potent effective modulators of the key interaction between the receptor binding domain (RBD) of SARS-CoV-2 spike protein and human ACE2. We also found that both compounds inhibited SARS-CoV-2 infection-induced cytopathic effect at micromolar concentrations. Therefore, in addition to the known TMPRSS2 activity of BHH; we report for the first time that the BHH and AMB pharmacophore has the capacity to target and modulate yet another key protein-protein interaction essential for the two known SARS-CoV-2 entry pathways into host cells. Altogether, the potent efficacy, excellent safety and pharmacologic profile of both drugs along with their affordability and availability, makes them promising candidates for drug repurposing as possible prophylactic and/or treatment options against SARS-CoV-2 infection.","Olaleye, O. A.; Kaur, M.; Onyenaka, C. C.","https://www.biorxiv.org/content/10.1101/2020.09.13.295691v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.13.295691v1?rss=1,2020-09-14,2020-09-14,,False
94,Non-permissive SARS-CoV-2 infection of neural cells in the developing human brain and neurospheres,"Coronavirus disease 2019 (COVID-19) was initially described as a viral infection of the respiratory tract. It is now known, however, that many other biological systems are affected, including the central nervous system (CNS). Neurological manifestations such as stroke, encephalitis, and psychiatric conditions have been reported in COVID-19 patients, but its neurotropic potential is still debated. Here, we investigate the presence of SARS-CoV-2 in the brain from an infant patient deceased from COVID-19. The susceptibility to virus infection was compatible with the expression levels of viral receptor ACE2, which is increased in the ChP in comparison to other brain areas. To better comprehend the dynamics of the viral infection in neural cells, we exposed human neurospheres to SARS-CoV-2. Similarly to the human tissue, we found viral RNA in neurospheres, although viral particles in the culture supernatant were not infective. Based on our observations in vivo and in vitro, we hypothesize that SARS-CoV-2 does not generate productive infection in developing neural cells and that infection of ChP weakens the blood-cerebrospinal fluid barrier allowing viruses, immune cells, and cytokines to access the CNS, causing neural damage in the young brain.","Pedrosa, C. d. S. G.; Goto-Silva, L.; Gomes, I. C.; Souza, L. R. Q.; Vit&oacuteria, G.; Ornelas, I. M.; Karmirian, K.; Mendes, M. A.; Salerno, J. A.; Puig-Pijuan, T.; Ver&iacutessimo, C.; Temerozo, J. R.; Furtado, D. R.; Borges, H. L.; Souza, T. M. L.; Guimar&atildees, M. Z. P.; Rehen, S.","https://www.biorxiv.org/content/10.1101/2020.09.11.293951v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.11.293951v1?rss=1,2020-09-14,2020-09-14,,False
95,Phylogenomic reveals multiple introductions and early spread of SARS-CoV-2 into Peru,"Peru has become one of the countries with the highest mortality rate from the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. To investigate early transmission event and genomic diversity of SARS-CoV-2 isolates circulating in Peru, we analyzed a total of 3472 SARS-CoV-2 genomes, from which 149 ones were from Peru to investigate how this novel virus became established in the country and to dissect the spread of the one in this area. Phylogenomic analysis revealed multiple, independent introductions of the virus mainly from Europe and Asia. In addition, we found evidence for community-driven transmission of SARS-CoV-2 as suggested by clusters of related viruses found in patients living in different Peru regions.","Juscamayta Lopez, E.; Tarazona, D.; Valdivia Guerrero, F.; Rojas Serrano, N.; Carhuaricra, D.; Maturrano Hernandez, L.; Gavilan Chavez, R.","https://www.biorxiv.org/content/10.1101/2020.09.14.296814v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296814v1?rss=1,2020-09-14,2020-09-14,,False
96,Self-assembling nanoparticles presenting receptor binding domain and stabilized spike as next-generation COVID-19 vaccines,"We present a comprehensive vaccine strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by combining antigen optimization and nanoparticle display. We first developed a receptor binding domain (RBD)-specific antibody column for purification and displayed the RBD on self-assembling protein nanoparticles (SApNPs) using the SpyTag/SpyCatcher system. We then identified the heptad repeat 2 (HR2) stalk as a major cause of spike metastability, designed an HR2-deleted glycine-capped spike (S2G{Delta}HR2), and displayed S2G{Delta}HR2 on three SApNPs with high yield, purity, and antigenicity. Compared to the RBD, the RBD-ferritin SApNP elicited a more potent murine neutralizing antibody (NAb) response on par with the spike. S2G{Delta}HR2 elicited two-fold-higher NAb titers than the proline-capped spike (S2P), while S2G{Delta}HR2 SApNPs derived from multilayered E2p and I3-01v9 60-mers elicited up to 10-fold higher NAb titers. The S2G{Delta}HR2-presenting I3-01v9 SApNP also induced critically needed T-cell immunity, thereby providing a next-generation vaccine candidate to battle the COVID-19 pandemic.

ONE-SENTENCE SUMMARYThe receptor binding domain and stabilized SARS-CoV-2 spike were displayed on nanoparticles as vaccine antigens and elicited potent immune responses.","He, L.; Lin, X.; Wang, Y.; Abraham, C.; Sou, C.; Ngo, T.; Zhang, Y.; Wilson, I. A.; Zhu, J.","https://www.biorxiv.org/content/10.1101/2020.09.14.296715v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.14.296715v1?rss=1,2020-09-14,2020-09-14,,False
97,CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention,"The ongoing pandemic of SARS-CoV-2 has brought tremendous crisis on global health care systems and industrial operations that dramatically affect the economic and social life of numerous individuals worldwide. Understanding anti-SARS-CoV-2 immune responses in population with different genetic backgrounds and tracking the viral evolution are crucial for successful vaccine design. In this study, we reported the generation of CD8 T cell epitopes by a total of 80 alleles of three major class I HLAs using NetMHC 4.0 algorithm for the spike protein of SARS-CoV-2, a key antigen that is targeted by both B cells and T cells. We found diverse capacities of S protein specific epitope presentation by different HLA alleles with very limited number of predicted epitopes for HLA-B*2705, HLA-B*4402 and HLA-B*4403 and as high as 132 epitopes for HLA-A*6601. Our analysis of 1000 S protein sequences from field isolates collected globally over the past few months identified three recurrent point mutations including L5F, D614G and G1124V. Differential effects of these mutations on CD8 T cell epitope generation by corresponding HLA alleles were observed. Finally, our multiple alignment analysis indicated the absence of seasonal CoV induced cross-reactive CD8 T cells to drive these mutations. Our findings provided molecular explanations for the observation that individuals with certain HLA alleles such as B*44 are more prone to SARS-CoV-2 infection. Studying anti-S protein specific CD8 T cell immunity in diverse genetic background is critical for better control and prevention of the SARS-CoV-2 pandemic.","Guo, H.; Guo, E.","https://www.biorxiv.org/content/10.1101/2020.09.10.290841v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.10.290841v1?rss=1,2020-09-10,2020-09-10,,False
98,Brain volumetric changes in the general population following the COVID-19 outbreak and lockdown,"The COVID-19 outbreak introduced unprecedented health-risks, as well as pressure on the financial, social, and psychological well-being due to the response to the outbreak1-4. Here, we examined the manifestations of the COVID-19 outbreak on the brain structure in the healthy population, following the initial phase of the pandemic in Israel. We pre-registered our hypothesis that the intense experience of the outbreak potentially induced stress-related brain modifications5-8. Volumetric changes in n = 50 participants scanned before and after the COVID-19 outbreak and lockdown, were compared with n = 50 control participants that were scanned twice prior to the pandemic. The pandemic provided a rare opportunity to examine brain plasticity in a natural experiment. We found volumetric increases in bilateral amygdalae, putamen, and the anterior temporal cortices. Changes in the amygdalae diminished as time elapsed from lockdown relief, suggesting that the intense experience associated with the pandemic outbreak induced volumetric changes in brain regions commonly associated with stress and anxiety9-11.","Salomon, T.; Cohem, A.; Ben-Zvi, G.; Gera, R.; Oren, S.; Roll, D.; Rozic, G.; Saliy, A.; Tik, N.; Tsarfati, G.; Tavor, I.; Schonberg, T.; Assaf, Y.","https://www.biorxiv.org/content/10.1101/2020.09.08.285007v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.08.285007v1?rss=1,2020-09-09,2020-09-09,,False
99,"Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - a cross-sectional study","BackgroundPrevalence of IgG antibodies against SARS-CoV-2 infection provides essential information for deciding disease prevention and mitigation measures. We estimate the seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar.

Methods2906 persons >18 years of age selected from hospital visitors across District Srinagar participated in the study. We tested samples for the presence of SARS-CoV-2 specific IgG antibodies using a chemiluminescent microparticle immunoassay-based serologic test.

ResultsAge- and gender-standardized seroprevalence was 3.6% (95% CI 2.9% to 4.3%). Age 30-69 years, a recent history of symptoms of an influenza-like-illness, and a history of being placed under quarantine were significantly related to higher odds of the presence of SARS-CoV-2 specific IgG antibodies. The estimated number of SARS-CoV-2 infections during the two weeks preceding the study, adjusted for test performance, was 32602 with an estimated (median) infection-to-known-case ratio of 46 (95% CI 36 to 57).

ConclusionsThe seroprevalence of SARS-CoV-2 specific IgG antibodies is low in the District. A large proportion of the population is still susceptible to the infection. A sizeable number of infections remain undetected, and a substantial proportion of people with symptoms compatible with COVID-19 are not tested.","Khan, S. M. S.; Qurieshi, M. A.; Haq, I.; Majid, S.; Bhat, A. A.; Nabi, S.; Ganai, N. A.; Zahoor, N.; Nisar, A.; Chowdri, I. N.; Qazi, T. B.; Kousar, R.; Lone, A. A.; Sabah, I.; Nabi, S.; Sumji, I. A.; Kawoosa, M. F.; Ayoub, S.","https://www.biorxiv.org/content/10.1101/2020.09.04.282640v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.09.04.282640v1?rss=1,2020-09-04,2020-09-04,,False
